Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections

Abstract

The present invention provides imidazo[1,2-a][1,8]naphthyridine derivatives of formula I, and more specifically 2-(2-(perfluoroethyl)-4-phenyl-imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole derivatives, and similar compounds, pharmaceutical compositions thereof. The present compounds are useful for treating and / or preventing viral infections, such as e.g. HBV, HDV or HSV, by enhancing one or more innate immune responses within a subject.

Description

[0001] IMIDAZONAPHTHYRIDINE COMPOUNDS USEFUL FOR ENHANCING INNATE IMMUNE RESPONSES CROSS-REFERENCE TO RELATED APPLICATION This application claims benefit of U.S. Provisional Application No. 63 / 609,511, filed December 13, 2023, the contents of which are hereby incorporated by reference in its entirety. FIELD OF THE INVENTION Provided are compounds, pharmaceutical compositions, methods for their preparation, and methods for their use in treating and / or preventing viral infections, and in particular, to certain compounds that can enhance one or more innate immune responses within a subject. BACKGROUND Antiviral drugs can work by interacting with the virus to reduce its pathogenicity or by targeting the host to improve the host's defense against the virus. Most antiviral drugs on the market (e.g., zanamivir for treating influenza, zidovudine for treating HIV, acyclovir for treating HSV, and entecavir for treating HBV) interact directly with the virus to reduce pathogenicity. However, viruses can mutate and, thereby, develop resistance to these types of antiviral drugs. Consequently, antiviral drugs aimed at directly targeting a virus are prone to decreased efficacy over time. As a result, there is an unmet need for an antiviral drug that targets the host rather than the virus directly. Therapeutic agents that bolster existing host immune mechanisms of viral defense, specifically the host innate immune response to infection, hold potential for treatment of multiple infections with a single agent. Interferon (IFN) is one of the cytokines secreted by immune cells, which activates immune cells and acts on various points in the virus life cycle to suppress the growth of viruses. Currently, injectable pegylated interferon (Peg-IFN) is available for general clinical use. A significant number of patients with Peg-IFN have a therapeutic effect regardless of whether they are HBe antigen positive or negative, and various side effects have been reported. To address these issues, WO2013 / 059559 to Glaxo SmithKline, LLC discloses non-nucleic acid, low- molecular-weight, antiviral therapeutics suitable for oral administration. For example, imidazonaphthyridine compound RO8191 and related compounds are reported as IFN mimetic drugs using HCV replicon cells. WO2018043747 to Kyoto University discloses imidazonaphthyridine compounds for treatment of HBV. There is a long-felt and unmet need for new non-nucleic acid, low-molecular-weight, antiviral therapeutics, that are not only suitable for oral administration, but have increased efficacy, safety, and pharmacokinetic profiles. SUMMARY The present disclosure provides, in part, imidazonaphthyridine compounds and pharmaceutical compositions thereof, useful for treatment of viral infections. In one aspect, the disclosure provides a compound of Formula I: Formula I or a pharmaceutically ac , variables are described in the detailed description. In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In another aspect, the disclosure provides a method of treating a viral infection in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. In another aspect, the disclosure provides a method of treating a viral infection in a subject in need thereof, comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. DETAILED DESCRIPTION The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. I. Definitions The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6 or 1-4 carbon atoms, referred to herein as C1-6alkyl and C1-4alkyl, respectively. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-butyl, 3-methyl-2- butyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2- pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl. The term “alkylene” as used herein refers to a biradical alkyl group. The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, a straight or branched group of 2-6 carbon atoms, referred to herein as C2-6alkenyl. Examples include, but are not limited to, vinyl, allyl, butenyl, and pentenyl. The term “alkenylene” as used herein refers to a biradical alkenyl group. The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6 carbon atoms, referred to herein as C2-6alkynyl. Examples include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylpropynyl. The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to oxygen (i.e., alkyl-O-). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 1-4 carbon atoms, referred to herein as C1-6alkoxy and C1-4alkoxy, respectively. Examples include, but are not limited to, methoxy, ethoxy, and isopropoxy. The term “alkoxyalkyl” as used herein refers to an alkyl group substituted with an alkoxy group. Exemplary alkoxyalkyl groups include, but are not limited to, a C1-6alkyl group substituted with a C1-3alkoxy or C1-4alkoxy group, referred to herein as C1-3alkoxyC1-6alkyl and C1-4alkoxyC1-6alkyl, respectively. Examples include, but are not limited to, CH3CH2OCH2-, CH3OCH2CH2- and CH3OCH2-. The term “alkoxyalkenyl” as used herein refers to an alkenyl group substituted with an alkoxy group. Exemplary alkoxyalkenyl groups include, but are not limited to, a C2-6alkenyl group substituted with a C1-3alkoxy or C1-4alkoxy group, referred to herein as C1-3alkoxyC2- 6alkenyl and C1-4alkoxyC2-6alkenyl, respectively. Examples include, but are not limited to, CH3CH2OCH2CH=CH-, CH3OCH=CH2- and CH3OCH2CH=CHCH2-. The term “carboxyalkyl” as used herein refers to an alkyl group substituted with one or more carboxyl groups. Exemplary carboxyalkyl groups include, but are not limited to, a C1-6alkyl or C1-4alkyl substituted with one or more carboxyl groups, referred to herein as carboxyC1-6alkyl and carboxyC1-4alkyl, respectively. The term “cyano” as used herein refers to CN. The term “formylalkyl” as used herein refers to an alkyl group substituted with one or more formyl groups. Exemplary formylalkyl groups include, but are not limited to, a C1-6alkyl or C1-4alkyl substituted with one or more formyl groups, referred to herein as formylC1-6alkyl and formylC1-4alkyl, respectively. The terms “halo” or “halogen” as used herein refer to F, Cl, Br or I. The term “haloalkyl” as used herein refers to an alkyl group substituted with one or more halogen atoms. Exemplary haloalkyl groups include, but are not limited to, a C1-6alkyl or C1-4alkyl substituted with one or more halo groups, referred to herein as haloC1-6alkyl and haloC1-4alkyl, respectively. Examples include, but are not limited to, -CH2F, -CHCl2, -CHF2, -CF3, CF3CH2-, CH3CF2-, CF3CCl2- and CF3CF2-. The term “haloalkenyl” as used herein refers to an alkenyl group substituted with one or more halogen atoms. Exemplary haloalkenyl groups include, but are not limited to, a C2-66alkenyl or C2-4alkenyl substituted with one or more halo groups, referred to herein as haloC2-6alkenyl and haloC2-4alkenyl, respectively. Examples include, but are not limited to, CH2=CHCF2CF2-, CF3CH2CH=CH- and CH2=CHCH2CHF-. The term “haloalkoxy” as used herein refers to an alkoxy group substituted with one or more halogen atoms. Exemplary alkoxy groups include, but are not limited to, a C1-6alkoxy or C1-4alkoxy substituted with one or more halo groups, referred to herein as haloC1-6alkoxy and haloC1-4alkoxy, respectively. Examples include, but are not limited to, CCl3O-, CF3O-, CHF2O- CF3CH2O-, and CF3CF2O-. The term “haloalkoxyalkyl” as used herein refers to an alkoxyalkyl group substituted with one of more halogen atoms. Exemplary haloalkoxyalkyl groups include, but are not limited to, a C1-3alkoxyC1-6alkyl or C1-4alkoxyC1-5alkyl group substituted with one or more halogen atoms, herein referred to as haloC1-3alkoxyC1-6alkyl and haloC1-4alkoxyC1-5alkyl. Examples include, but are not limited to, CF3CH2OCH2-, CH3OCH2CF2- and CH3OCFH-. The term “haloalkoxyalkenyl” as used herein refers to an alkoxyalkenyl group substituted with one of more halogen atoms. Exemplary haloalkoxyalkenyl groups include, but are not limited to, a C1-3alkoxyC2-6alkenyl or C1-4alkoxyC2-4alkenyl group substituted with one or more halogen atoms, herein referred to as haloC1-3alkoxyC2-6alkenyl and haloC1-4alkoxyC2-4alkenyl. Examples include, but are not limited to, CF3CF2OCH2CH=CH-, CH3OCF=CH2- and CH3OCH2CH=CHCF2-. The terms “hydroxy” and “hydroxyl” as used herein refer to OH. The term “hydroxyalkyl” as used herein refers to an alkyl group substituted with one or more hydroxy groups. Exemplary hydroxyalkyl groups include, but are not limited to, a C1-6alkyl or C1-4alkyl substituted with one or more hydroxy groups, referred to herein as hydroxyC1-6alkyl and hydroxyC1-4alkyl, respectively. Examples include, but are not limited to, HOCH2-, HOCH2CH2-, CH3CH(OH)CH2-, (CH3)2C(OH)CH2-, and HOCH2CH(OH)CH2-. The term “hydroxyalkenyl” as used herein refers to an alkenyl group substituted with one or more hydroxy groups. Exemplary hydroxyalkenyl groups include, but are not limited to, a C2-6alkenyl or C2-4alkenyl substituted with one or more hydroxy groups, referred to herein as hydroxyC2-6alkenyl and hydroxyC2-4alkenyl, respectively. Examples include, but are not limited to, CH2=CHCH(OH)CH2-, CH3CH(OH)CH=CH- and HOCH2CH2CH2=CHCH2-. The term “hydroxyalkoxy” as used herein refers to an alkoxy group substituted with one or more hydroxy groups. Exemplary hydroxyalkoxy groups include, but are not limited to, a C1-6alkoxy or C1-4alkoxy substituted with one or more hydroxy groups, referred to herein as hydroxyC1-6alkoxy and hydroxyC1-4alkoxy, respectively. Examples include, but are not limited, to HOCH2O-, HOCH2CH2O-, CH3CH(OH)CH2O-, (CH3)2C(OH)CH2O-, and HOCH2CH(OH)CH2O-. The term “hydroxyhaloalkyl” as used herein refers to an haloalkyl group substituted with one or more hydroxy groups. Exemplary hydroxyalkyl groups include, but are not limited to, a haloC1-6alkyl or haloC1-4alkyl substituted with one or more hydroxy groups, referred to herein as hydroxyhaloC1-6alkyl and hydroxyhaloC1-4alkyl, respectively. Examples include, but are not limited to, HOCFH-, HOCH2CF2-, CF3CH(OH)CH2-, (CH3)2C(OH)CFH-, and HOCH2CH(OH)CF2-. The term “monocycloalkyl” as used herein refers to a saturated monocyclic hydrocarbon group of, for example, 3-6 carbons, referred to herein as monoC3-6cycloalkyl. Examples include, but are not limited to, cyclooctyl, cycloheptyl. cyclohexyl, cyclopentenyl, cyclobutyl and cyclopropyl. The term “monocycloalkenyl” as used herein refers to a partially unsaturated monocyclic hydrocarbon group of, for example, 4-7 carbons, referred to herein as monoC4-7cycloalkenyl. Exemplary monocyclic cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. The term “monoheterocycloalkyl” refers to a monocycloalkyl group, for example a monoC3-7cycloalkyl, wherein 1-3 of the carbon atoms are replaced with independently selected heteroatoms, such as nitrogen, oxygen, and sulfur (including its oxidation states: S(O) and SO2), herein referred to as mono3-7heterocycloalkyl. Examples of mono3-7heterocycloalkyl groups include, but are not limited to, aziridinyl, oxiranyl, thiarinyl 1,1-dioxide, oxetanyl, azetidinyl, thietanyl 1,1-dioxide, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydro-2H-pyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl 1,1,dioxide, and piperazinyl. The term “monoheterocycloalkenyl” refers to a monocycloalkyl group, for example a monoC4-7cycloalkenyl, wherein 1-3 of the carbon atoms are replaced with independently selected heteroatoms, such as nitrogen, oxygen, and sulfur (including its oxidation states: S(O) and SO2), herein referred to as mono4-7heterocycloalkenyl. Examples of mono4-7heterocycloalkenyl groups include, but are not limited to, 2,3-dihydro-1H-pyrrolyl, 2,5-dihydro-1H-pyrrolyl, 4,5-dihydro- 1H-pyrazolyl, 2,3-dihydro-1H-pyrazolyl, 4,5-dihydro-1H-imidazolyl, 2,3-dihydro-1H- imidazolyl, 2,3-dihydrothiophenyl, 2,5-dihydrothiophenyl, 4,5-dihydrothiazolyl, 2,3- dihydrothiazolyl, 4,5-dihydroisothiazolyl, 2,3-dihydroisothiazolyl, 2,3-dihydrofuranyl, 2,5- dihydrofuranyl, 4,5-dihydrooxazolyl, 2,3-dihydrooxazolyl, 4,5-dihydroisoxazolyl, 2,3- dihydroisoxazolyl, 3,4-dihydropyridinyl, 2,3-dihydropyridinyl, 2,3,4,5-tetrahydropyridinyl, 1,6- dihydropyridazinyl, 4,5-dihydropyridazinyl, 3,4,5,6-tetrahydropyridazinyl, 4,5- dihydropyrimidinyl, 1,2,5,6-tetrahydropyrimidinyl, 1,2-dihydropyrimidinyl, 1,2- dihydropyrazinyl, 2,3-dihydropyrazinyl, 1,2,3,6-tetrahydropyrazinyl, 4H-1,4-oxazinyl, 3,4- dihydro-2H-1,4-oxazinyl, 4H-1,4-thiazinyl, and 3,4-dihydro-2H-1,4-thiazinyl. The term “RaRbNalkyl” as used herein refers to an alkyl group substituted with one or more RaRbN groups, wherein Raand Rbdefined herein. Exemplary RaRbNalkyl groups include, but are not limited to, a C1-6alkyl or C1-4alkyl substituted with one or more RaRbN groups, referred to herein as RaRbN C1-6alkyl and RaRbNC1-4alkyl, respectively. As used herein, when a bicyclic ring is shown with a floating point of attachment and / or floating substituents, for exampl it signifies that the bicyclic ring can be attached via a carbon atom on eit bstituents (e.g.33 , the R group(s)) can be independently attached to either or both rings. The terms “Individual,” “patient,” and “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds or pharmaceutical compositions of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, dogs, primates, and the like). The mammal treated in the methods of the disclosure is desirably a mammal in which treatment of HBV infection is desired. The term “Pharmaceutically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards. The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, fillers, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable excipients. The term "pharmaceutically acceptable salt(s)" as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3- naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt. The term “therapeutically effective amount” or “effective amount” as used herein refers to the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g., mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician. The compounds or pharmaceutical compositions of the disclosure are administered in therapeutically effective amounts to treat a disease. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and / or prophylactic effect. The term “treating” as used herein includes any effect, e.g., lessening, reducing, modulating, or eliminating, a viral infection, that results in the improvement of the disease. The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “(-),” “R” or “S,” depending on the configuration of substituents around the stereogenic carb n atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon- carbon double bond. The symbol denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond. Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers. Substituents around a carbocyclic or heterocyclic ring may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis / trans.” Individual enantiomers and diastereomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well-known methods, such as chiral- phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre- existing one, are well known in the art. Stereoselective syntheses encompass both enantiomeric and diastereoselective transformations and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009. The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in a crystalline form. The disclosure also embraces isotopically labeled compounds of the disclosure which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as2H,3H,13C,14C,15N,18O,17O,31P,32P,35S,18F, and36Cl, respectively. For example, a compound of the disclosure may have one or more H atom replaced with deuterium. Certain isotopically-labeled disclosed compounds (e.g., those labeled with3H and14C) are useful in compound and / or substrate tissue distribution assays. Tritiated (i.e.,3H) and carbon- 14 (i.e.,14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e.,2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. II. Imidazonaphthyridine Compounds In one aspect, the present disclosure provides a compound of Formula I Formula I , or a pharmaceutical y accepta e sa t t ereo , w erein: X0is O or S; X1is N or CH; X2is O or S; Raand Rbare independently selected for each occurrence from the group consisting of hydrogen and C1-4alkyl; R0is haloC1-6alkyl or monoC3-7cycloalkyl; R1is selected from the group consisting of: R3is hydrogen, halo, OH, cyano, formyl, C1-4alkyl, haloC1-4alkyl, C1-4alkenyl, haloC1-4alkenyl, formylC1-4alkyl, hydroxyC1-4alkyl, RaRbN-alkyl-, C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl-, phenylC(O)OC1-4alkyl- or R5R6P(O)OC1-4alkyl-; R4is independently selected for each occurrence from the group consisting of halo, OH, CN, NO2, NRaRb, RaRbNC(O)-, carboxyl, formyl, C1-4alkyl, haloC1-4alkyl, carboxyC1-4alkyl-, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxyC1-5alkyl-, C1-4alkoxy, haloC1-4alkoxy, C1-4alkylC(O)-, haloC1-4alkylC(O)-, C1-4alkylC(O)O-, haloC1-4alkylC(O)O-, C1-4alkylSO2-, haloC1-4alkylSO2-, C1-4alkoxyC1-5alkyl-, haloC1-4alkoxyC1-5alkyl-, C1-4alkylC(O)OC1-5alkyl-, haloC1-4alkylC(O)OC1-5alkyl-, C1-4alkoxyC(O)C1-5alkyl-, haloC1-4alkoxyC(O)C1-5alkyl-, phenylC(O)OC1-4alkyl-, C1-4alkoxyC(O)OC1-4alkyl-, C1-4alkoxyC1-5alkyl-O-, haloC1-4alkoxyC1-5alkyl-O-, C1-4alkoxyC1-5alkyl-NRa-, haloC1-4alkoxyC1-5alkyl-NRa-, C1-4alkoxyC(O)OC1-5alkyl-, haloC1-4alkoxyC(O)OC1-5alkyl-, hydroxyC1-4alkylC(O)OC1-4alkyl-, C1-4alkoxyC(O)-C1-4alkylene-C(O)OC1-4alkyl-, C1-4alkoxyC(O)-C1-4alkenylene-C(O)OC1-4alkyl-, carboxyC1-4alkylC(O)OC1-4alkyl-, carboxyC1-4alkenylC(O)OC1-4alkyl-, R7R8P(O)OC1-4alkyl-, CH3CH2O- (CH2CH2O)n-C1-4alkyl-, CH3CH2O-(CH2CH2O)n-CH2CH2C(O)OC1-4alkyl-, CH3CH2O- (CH2CH2O)n-C(O)OC1-4alkyl-, monoC3-7cycloalkyl, phenyl and pyridyl, wherein the monoC3-7cycloalkyl, phenyl and pyridyl is optionally substituted with 1-3 groups independently selected from the group consisting of halo, OH, C1-4alkyl and haloC1-4alkyl; R4ais hydrogen or C1-4alkyl; R5, R6, R7and R8are independently selected from the group consisting of: OH, C1-4alkoxy, phenoxy, C1-4alkylC(O)O-C1-4alkylene-O- and C1-6alkoxyC(O)-C1-4alkylene-NRa-; or R5and R6together form a -OCH2CH2CH2O- group optionally substituted with a phenyl or pyridyl, wherein the phenyl or pyridyl is optionally substituted with halo; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. x is 0 or 1; w is 0, 1 or 2; and v is 0, 1, 2 or 3. The following embodiments further describe a compound of Formula I, or a pharmaceutically acceptable salt thereof. It will be appreciated that all chemically allowable combinations of the embodiments described herein are envisioned as further embodiments of the invention. In certain embodiments, X0is O. In certain embodiments, X0is S. In certain embodiments, X1is N. In certain embodiments, X1is CH. In certain embodiments, R0is haloC1-6alkyl. In certain embodiments, R0is CF3, CF3CF2or CF3CF2CF2. In certain embodiments, R0is CF3CF2. In certain embodiments, R1is . In certain embodiments, R2is hydrogen. In certain embodiments, R2is halo. In certain embodiments, R3is hydrogen. In certain embodiments, R3isC1-4alkyl, haloC1-4alkyl, C1-4alkenyl, haloC1-4alkenyl,formylC1-4alkyl, hydroxyC1-4alkyl, RaRbN-alkyl-, C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl-, phenylC(O)OC1-4alkyl- or R5R6P(O)OC1-4alkyl-. In certain embodiments, R3is OH or hydroxyC1-4alkyl. In certain embodiments, R3isHOCH2- or HOCH2CH2-.In certain embodiments, R3is R5R6P(O)OC1-4alkyl-. In certain embodiments, R3is C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl- or phenylC(O)OC1-4alkyl-. In certain embodiments, R4is OH or hydroxyC1-4alkyl. In certain embodiments, R4is HOCH2- or HOCH2CH2-. In certain embodiments, R4is R5R6P(O)OC1-4alkyl-. In certain embodiments, R4is C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl- or phenylC(O)OC1-4alkyl-. III. Methods of Use Without being bound by any theory, since the compounds of the present disclosure behave as interferon mimicking agents (IFN mimetic agents), it is believed that may exhibit their antiviral activity through a variety of mechanisms. One such mechanism involves modulating the expression of interferon-stimulated genes (ISGs) through the janus kinase / signal transducer and activator (JAK / STAT) pathway, a common target for attack by a variety of viruses (Fleming, 2016, herein incorporated by reference with regard to such background teaching). Like other antiviral agents – the compounds of the present disclosure may also function as protease or polymerase inhibitors, disrupt the viral replication machinery or have general anti-viral activity against viral components. The presence of these mechanisms in a broad group of viruses suggest the compounds disclosed herein may provide therapeutic anti-viral activity against a diverse group of viruses. Thus, one aspect described herein is a method of treating a hepatitis B infection (HBV) in a patient in need thereof is provided, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a hepatitis B infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. With regard to HBV / hepatitis D (HDV) coinfection or superinfection, HDV encodes HDAg, the HDV protein responsible for HDV RNA replication. HDV infection is facilitated by the interaction of HDAg with HBV viral envelope protein HBsAg, for both entry into the hepatocytes and assembly and release of the HDV virions (Negro, 2014). Thus, because HDV infection is dependent on the presence of an existing HBV infection, strategies for treating HBV / HDV coinfection may focus on targeting HBV alone, HDV alone or both viruses together. Thus, the present disclosure also contemplates a method of treating an HBV or HDV infection, or HBV / HDV coinfection, in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating an HBV or HDV infection or HBV / HDV coinfection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. In some aspects, the disclosure provides a method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, in combination with one or more other HBV agents each selected from the group consisting of HBV capsid assembly promoters, HBV viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7 / 9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists. In some embodiments, the disclosure provides a method of treating a hepatitis B infection in a patient in need thereof, comprising administering an amount of a disclosed compound, and administering another HBV capsid assembly promoter therapeutic. Other combinations contemplated herein include administering a first compound selected from any one of the disclosed compounds, in combination with any available HBV treatment, including not limited to, entecavir, tenofovir, Baraclude, Viread, lamivudine, Vemlidy, Hepsera, Epivir-HBV, adefovir, epivir tenofovir alafenamide, and other suitable HBV drugs. In some aspects, the disclosure further provides a method of treating HBV or HDV infection or HBV / HDV coinfection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, and one or more other additional antivirals, the one or more additional antivirals include HDV therapies, such as lonafarnib, and one or more of HBV agents each selected from the group consisting of HBV capsid assembly promoters, HBV viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7 / 9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists. In some embodiments, the disclosure provides a method of treating a HBV or HDV infection or HBV / HDV coinfection in a patient in need thereof, comprising administering an amount of a disclosed compound, and administering another HBV therapeutic or an HDV therapeutic. Another IFN mimetic, RO 8191 has demonstrated antiviral activity against hepatitis C virus (HCV) (Wang et al., 2015), Corona viruses (WO2022 / 049521), and Zika virus (ZIKV) (Fernandes et al., 2021). Given that the compounds of the instant disclosure are also IFN mimicking agents anti-viral activity against HCV, Corona virus and Zika virus is also contemplated herein. Thus, another aspect described herein is a method of treating a hepatitis C infection (HCV) in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a hepatitis C infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. In some aspects, the disclosure provides a method of treating a hepatitis C infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, in combination with suitable treatments for HCV including, but not limited to, lbasvir / Grazoprevir (Zepatier), Glecaprevir / Pibrentasvir (Mavyret), Sofosbuvir / Ledipasvir (Harvoni), Sofosbuvir / Velpatasvir (Epclusa), second line hepatitis C medications such as Sofosbuvir / Velpatasvir / Voxelaprevir (Vosevi), and other suitable HCV drugs. Coronaviruses are another possible viral target for the compounds of the present disclosure (See, for example, WO2022 / 049521). Thus, another aspect of the present disclosure provides methods for treating viral infection, wherein said viral infection comprises one or more viruses from the Coronaviridae family including human coronavirus, Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome coronavirus (MERS- CoV) and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV- 2). The disease caused by these viruses are SARS (SARS-CoV), MERS (MERS-CoV) and COVID-19 (SARS- CoV-2). Another aspect described herein, are methods for treating viral infections, and the disease caused by such viral infection, wherein said viral infection is SARS-CoV, and the resulting disease is SARS, MERS-CoV, and the resulting disease is MERS, or SARS-CoV-2, and the disease is COVID-19. In some aspects, the disclosure provides a method of treating any Coronaviridae viral infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, in combination with suitable treatments for Coronavirus infection including, but not limited to, nirmatrelvir, ritonavir, Lagevrio (molnupiravir), baricitinib, and the various coronavirus vaccines and other suitable Coronavirus drugs. Another aspect described herein, is a method of treating a Zika virus (ZIKV) viral infection in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a ZIKV infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. In some aspects, the disclosure provides a method of treating a Zika virus infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, in combination with suitable treatments for ZIKV infection. Although there are no medications to treat ZIKV, because treatment includes over the counter use of pain, anti-inflammatory drugs, suitable drugs for combining administration of the compounds of the instant disclosure include acetaminophen, ibuprofen, non-steroidal anti-inflammatory drugs and hydration therapies. Human papillomavirus (HPV) is another common sexually transmitted virus with more than 100 known varieties. Interferons have been successfully used to treat HPV infections, making this virus an ideal candidate for treatment by the compounds of the present disclosure. Thus, another aspect described herein, is a method of treating HPV infection in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a HPV infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. Combination therapy with the compounds disclosed herein, and known HPV drugs are also contemplated herein. In some aspects, the disclosure provides a method of treating any HPV viral infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, in combination with suitable treatments for HPV infection including, but not limited to, condylax (podofilox), trichloroacetic acid, aldara (imiquimod), zyclara, keratoyltic agents, immune response modifiers, and various commonly used HPV vaccines. Prion infection results in fatal brain diseases and encephalopathies in both humans and animals. Recombinant and IFN mimicking interferon therapy have both been found to possible protect neurons from prion infections (Ishibashi, 2019). Thus, one aspect described herein is a method of treating prion infection in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a prion infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. Chikungunya virus (CHIKV) and Dengue virus are both related mosquito-borne viruses with no approved therapies. Studies have demonstrated that CHIKV replication has been found to be inhibited by an agonist of Liver X receptor (LXR-623) by activation of the interferon signaling pathway (Hwang et al., 2019), and halofuginone has been found to work synergistically with another IFN mimicking agent. Thus, both CHIKV and Dengue virus represents yet another group of viruses ideally suited for therapy with the compounds described herein. Without being bound by any theory, it is possible the compounds of the present disclosure could demonstrate a synergistic effect with LXR-623 agonists for the treatment of CHIKV and / or with halofuginone for the treatment of both CHIV and Dengue virus. Thus, another embodiment described herein is a method of treating CHIKV by administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In one aspect, a method of treatment would include administering any of the disclosed compounds in combination with LXR-623. In another aspect described herein is a method of treating CHIKV virus comprising administering to a subject in need thereof, a combination of the compounds disclosed herein and LXR-623 or halofuginone. In yet another aspect, is a method of treating Dengue virus comprising administering to a subject in need thereof, a combination of the compounds disclosed herein and halofuginone. Without being bound by any theory, it is further understood that the compounds of the present disclosure may be useful for the treatment of human norovirus (HNV) and encephalomyocarditis virus (EMCV) – both of which have been found to be respond to interferon-mediated antiviral therapy (de Graff et al., 2016; Campillay-Veliz et al., 2020)). Thus, another aspect described herein is a method of treating HNV infection in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a EMCV infection in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and / or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). Further contemplated herein is a method for treating any of the viral infections described herein, in a subject that has been diagnosed with said viral infection or is at risk of developing said viral infection comprising administering to said subject, any one of the compounds described herein. Another aspect described herein, is a method for enhancing the immune response to a viral infection from any of the viruses described herein, in a subject that is immunocompromised or is at risk of developing an immunocompromised immune system, comprising administering to said subject, any of the compound as described herein. IV. Administration and Formulations In further embodiments, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The chemical entities are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease. The compounds of the present invention can also be supplied in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable inorganic and organic acids and bases. Pharmaceutically acceptable inorganic bases include metallic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like and in their usual valences. Exemplary salts include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, including in part, trimethylamine, diethylamine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine; substituted amines including naturally occurring substituted amines; cyclic amines; quaternary ammonium cations; and basic ion exchange resins, such as arginine, betaine, caffeine, choline, Ν,Ν-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. Illustrative pharmaceutically acceptable acid addition salts of the compounds of the present invention can be prepared from the following acids, including, without limitation formic, acetic, propionic, benzoic, succinic, glycolic, gluconic, lactic, maleic, malic, tartaric, citric, nitic, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, hydrochloric, hydrobromic, hydroiodic, isocitric, trifluoroacetic, pamoic, propionic, anthranilic, mesylic, oxalacetic, oleic, stearic, salicylic, p-hydroxybenzoic, nicotinic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, phosphoric, phosphonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, sulfuric, salicylic, cyclohexylaminosulfonic, algenic, β-hydroxybutyric, galactaric and galacturonic acids. Preferred pharmaceutically acceptable salts include the salts of hydrochloric acid and trifluoroacetic acid. All of the above salts can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention. For example, the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionization in the salt may vary from completely ionized to almost non-ionized. Lists of suitable salts are found in Remington's Pharmaceutical Sciences. 17th ed., Mack Publishing Company, Easton, Pa., 1985, p.1418, the disclosure of which is hereby incorporated by reference only with regards to the lists of suitable salts. In general, the chemical entities provided will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the chemical entity, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the chemical entity used, the route and form of administration, and other factors. The drug can be administered more than once a day, such as once or twice or three times a day. Therapeutically effective amounts of the chemical entities described herein may range from approximately 0.01 to 200 mg per kilogram body weight of the recipient per day; such as about 0.01-100 mg / kg / day, for example, from about 0.1 to 50 mg / kg / day. Thus, for administration to a 70 kg person, the dosage range may be about 7-3500 mg per day. In addition, the amount of the chemical entity in a composition can vary within the full range employed by those skilled in the art. Typically, the composition will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of at least one chemical entity described herein based on the total composition, with the balance being one or more suitable pharmaceutical excipients. In certain embodiments, the at least one chemical entity described herein is present at a level of about 1-80 wt%. In certain embodiments, the chemical entities will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), sublingually, subcutaneously, topically, intrapulmonarilly, vaginally, rectally, or intraocularly, or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. In other embodiments, oral administration with a convenient daily dosage regimen that can be adjusted according to the degree of disorder or disease may be used. The choice of administration route and / or formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance. In one embodiment, the compounds of the present invention may be administered topically to the diseased area on the skin or mucous membranes of a subject. In another embodiment, the compounds of the present invention may be administered topically to the diseased area on the skin or mucous membranes of a subject so that the topical administration allows for the compound to penetrate into the subject's skin layer keratinocyte cells. In some embodiments, the compositions are comprised of, in general, at least one chemical entity described herein in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of at least one chemical entity described herein. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Liquid carriers, for injectable solutions, include water, saline, aqueous dextrose, and glycols. Pharmaceutical compositions or formulations include solid, semi-solid, liquid and aerosol dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols or the like. The chemical entities can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and / or timed, pulsed administration at a predetermined rate. In certain embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose. The chemical entities described herein can be administered either alone or more typically in combination with a conventional pharmaceutical carrier, excipient or the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%; in certain embodiments, about 0.5% to 50% by weight of a chemical entity. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. In certain embodiments, the compositions will take the form of a pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) is encapsulated in a gelatin capsule. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. at least one chemical entity and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of chemical entities contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the chemical entities and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. In certain embodiments, the composition will comprise from about 0.2 to 2% of the active agent in solution. In one embodiment, the compounds of the present invention can be formulated into dermatological topical delivery formulations. Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For treatments of external tissues, such as skin, the formulations may be applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil- in-water cream base or a water-in-oil base. In addition to the compounds of the present invention, the compositions herein may additionally include an organic solvent, an adhesive, plasticizer, and a water swellable polymer. The organic solvent may be one or more of dimethylsulfoxide (DMSO), N,N'- dimethylacetamide (DMA), N',N'-dimethylformamide (DMF), dioxane, tetraglycol, or the like. Appropriate adhesives for use in the invention include, but are not limited to, polyvinyl alcohol, polyethylene oxides, polyethylene glycols of molecular weight 3350 and higher, hydroxypropylcellulose, and povidone. Polyvinyl alcohol is preferred. The adhesive is typically present in an amount from about 10 to 75% by weight, preferably about 45-55% by weight, and most preferably about 50% by weight of the composition. The compositions herein may optionally also include a plasticizer. Suitable plasticizers are typically high-boiling, water-soluble organic compounds containing hydroxyl, amide, or amino groups. Such plasticizers include, but are not limited to, soy, egg or synthetic lecithin, ethylene glycol, tetraethylene, hexamethylene, nonaethylene glycol, formamide, ethanolamine salts, water, glycerin, or combinations thereof. Such plasticizers are well known in the art. A plasticizer is therefore preferably included in the formulation to provide these benefits. The plasticizer is typically present in the composition in an amount ranging from about 0.4-2.0% by weight, with about 1-2% by weight being preferred, and about 0.9% by weight being most preferred. The composition may also include a water swellable polymer which acts as an extender and serves to thicken the composition. Such water swellable polymers are well known in the art and include, but are not limited to, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, methyl ethyl cellulose, sodium carboxymethylcellulose, gums, carboxyvinyl polymer, hydroxyethyl cellulose, cornstarch, casein, urea, dextrin, and fume silica. The filler is typically present in an amount from about 1-10% by weight, preferably about 3-6% by weight, with about 4.67% by weight being most preferred. The present invention is further directed to a method of treating warts by applying the pharmaceutical composition(s) topically to the location on the skin where the warts are present. The method of the invention comprises topically applying to a wart on an individual a therapeutically effective amount of the compositions of the invention. The composition may be applied using an applicator, for example, a swab, sponge, finger cot or a toothpick. While some compositions of this invention can be adhesive in and of themselves, in another embodiment of the invention, the method further comprises occluding the wart with an occluding agent to aid the composition's absorption into the wart, protect the composition from rubbing off, and also further keratolytic activity. Many occluding agents are known to those skilled in the art. These include, but are not limited to, bandages, plastic wrap, and adhesive tape, for example, duct tape. The compositions of the invention may further include a variety of substances, including suitable stabilizers, buffers, thickeners, lubricants, wetting, and dissolving agents as well as colorings, moisturizers, preservatives, and fragrances. These minors are added in small amounts and are conventionally known in pharmaceutical formulation work to enhance elegance. Such minors typically comprise less than about 1% of the overall composition. In still other embodiments, the compounds of the present invention can be formulated into dermatological delivery formulations, such as a stick-gel, which can be used to target the delivery of the compound directly onto the site of action. For example, if the compounds of the present invention are intended to be used as a treatment for papillomavirus induced warts, then the compound(s) may be formulated into a stick-gel that can apply the compounds in a formulation directly to the surface of the wart. In still other embodiments, the stick-gel application formulation can be based on a PSAs (Pressure Sensitive Adhesives) concept. PSAs, unlike structural adhesives or sealants, differ in that the adhesive-substrate interface does not resist separation when the adhesive is peeled off. In other words, PSAs are intended to show adhesive failure, especially when skin is the substrate, whereas this would be a major fatal flaw for cement and glue. Developing a suitable PSA-GeI for a targeted adherend to treat a skin common wart, takes the following two critical adhesive attributes into consideration: surface activity and visco-elastic properties. As such, these attributes are associated to the three steps of adhesion process. The first step involves contact between the adhesive and the surface. This dynamic step is known as "bonding or sticking" and is dependent on wetting behavior and quick spreadability of the adhesive composition. The second step "adhering" relies on the capacity of the adhesive to remain in contact with surface. This is important for treating warts where the active should be adherent to the warts long enough to exert its intended action. Flowability and creep resistance are the physical characteristics that contribute to maintain the established bond and stick. During this more static phase, the adhesion will build up if the adhesive-to-surface interactions increase (e.g., interpenetration). The third step "debonding" is also dynamic. It consists in separating the adhesive-stick from the surface by means of a peel release process. The peel adhesion property of the adhesive composition will direct the force required to break the bond in an adhesive failure mode. The formulation composition to achieve all these attributes can comprise suitable hydrophilic polymers incorporated into a gel matrix containing the active drug in solution. Large organic macromolecules that are either natural or synthetic hydrophilic polymers (e.g., hydroxy propyl methyl cellulose, ethyl cellulose, etc.) on the other hand, exist as randomly coiled chains that entangle with each other to form the gel structure. The nature of the solvent determines whether the gel is a hydrogel (water based) or an organogel (nonaqueous solvent). For example, gels prepared with hydroxyethyl cellulose containing water are hydrogels, whereas gels prepared with polyethylene-containing mineral oil (PIastibase) are organogels. Another class of gels, called thermally sensitive gels, are prepared from poloxamers. In addition to hydrophilic polymers, silicones are versatile materials permitting the design of various transdermal and topical drug delivery forms. The substantivity to skin can be adjusted from hours to one week in duration. Moreover, the hydrophobic, highly open, and mobile dimethylsiloxane network allows for the preparation of semi-occlusive matrices, permeable to many molecules including the compound(s) of the present invention. In other embodiments of the present invention, there is provided sustained release of certain compounds described herein from silicone pressure sensitive adhesive matrices. This capability can also be expanded to other types of silicone matrices including fillerless or reinforced elastomers. As such, modulation of the release of certain compounds of the present invention could enhance drug targeting and therapeutic effectiveness. The silicone formulations could include a loosely cross-linked fillerless elastomer dispersion (Dow Corning® 9040 Silicone Elastomer Blend), a fully cross-linked fillerless elastomer (Dow Corning® 7-9800 A&B Soft Skin Adhesive), a rubber film-forming dispersion (Dow Corning® 7-5300 Film-In-Place Coating), and / or a visco-elastic system (Dow Corning® PSA 7-4502 and 7-4602 pressure sensitive adhesive. In certain embodiments, the compound(s) of the present invention could be formulated in the different silicone and polymer matrices along with the following excipients: surfactants, citric-sodium bicarbonates, and / or carbomer 974. Pharmaceutical compositions of the chemical entities described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition have diameters of less than 50 microns, in certain embodiments, less than 10 microns. For delivery via inhalation the chemical entity can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration. There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI). Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient's respiratory tract. MDIs typically are formulation packaged with a compressed gas. Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent. DPI dispenses therapeutic agents in the form of a free- flowing powder that can be dispersed in the patient's inspiratory air stream during breathing by the device. To achieve a free-flowing powder, the therapeutic agent is formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation. Likewise, compressed gases may be used to disperse a chemical entity described herein in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990). Recently, pharmaceutical compositions have been developed for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size. For example, U.S. Patent No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a cross-linked matrix of macromolecules. U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability. V. Examples The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials. At least some of the compounds identified as “intermediates” herein are contemplated as compounds of the disclosure. Abbreviations: AcOH Acetic acid ACN Acetonitrile 9-BBN 9-Borabicyclo[3.3.1]nonane DAST Diethylaminosulfur trifluoride DCE 1,2-Dichloroethane DCM Dichloromethane DIBAL-H Diisobutylaluminium hydride DIEA Diisopropyl ethylamine DMAP 4-Dimethylaminopyridine DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide DPPF 1,1’-Bis(diphenylphosphino)ferrocene EA, EtOAc Ethyl acetate EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Et3N Triethylamine EtOH Ethanol h, hr Hour(s) HPLC High performance liquid chromatography IPA, i-PrOH Isopropyl alcohol LCMS Liquid chromatography–mass spectrometry LDA Lithium diisopropylamide MeOH Methanol Mn(dmp)3Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)manganese(III) MsCl Methanesulfonyl chloride MTBE Methyl tertiary-butyl ether NBS N-Bromosuccinimide Pd(dba)2Bis(dibenzylideneacetone)palladium(0) PE Petroleum ether TsOH p-Toluenesulfonic acid Rf Retention factor value rt, r.t. Room temperature SFC Supercritical Fluid Chromatography TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin-layer chromatography I. Synthesis of the common intermediates (A-C). Intermediate A: ethyl 2-chloro-4-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate Step 1. Synthesis of 7-amino-4-(1,1,2,2,2-pentafluoroethyl)-1H-1,8-naphthyridin-2-one (A- 2). A solution of ethyl 4,4,5,5,5-pentafluoro-3-oxopentanoate (A-1) (30 g, 128.138 mmol) and 2,6-diaminopyridine (13.98 g, 128.138 mmol) in toluene (300 mL) was stirred for 10 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature and diluted with MTBE (200 mL). The precipitated solids were collected by filtration and dried over air to give 7-amino-4-(1,1,2,2,2-pentafluoroethyl)-1H-1,8-naphthyridin-2-one (A-2) (27 g, 75.48%) as a yellow solid. MS (ESI, m / z): calcd. for C10H6F5N3O: 279.0; Found: 280.1 [M + 1]+. Step 2. Synthesis of ethyl 2-oxo-4-(perfluoroethyl)-1,2-dihydroimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (A-3). A solution of 7-amino-4-(1,1,2,2,2- pentafluoroethyl)-1H-1,8-naphthyridin-2-one (A-2) (27.00 g, 96.72 mmol) and ethyl 3-bromo-2- oxopropanoate (37.72 g, 193.43 mmol) in DMF (300 mL) was stirred for 10 hrs at 70°C under nitrogen atmosphere. The reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (500 mL) and the aqueous layer was extracted with EtOAc (300 mL x 2). The combined organic phase was dried over anhydrous Na2SO4and concentrated in vacuum to give the crude product which was purified by flash chromatography (PE: THF=1:1 (v / v)) mixture to give ethyl 2-oxo-4-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2- a]1,8-naphthyridine-8-carboxylate (A-3) (13 g, 35.82%) as a yellow solid. MS (ESI, m / z): calcd. for C15H10F5N3O3: 375.0; Found: 376.1 [M + 1]+. Step 3. Synthesis of ethyl 2-chloro-4-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8- carboxylate (A). A solution of ethyl 2-oxo-4-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2-a]1,8- naphthyridine-8-carboxylate (A-3) (13.00 g, 34.64 mmol) and phosphorus oxychloride (26.56 g, 173.22 mmol) in a mixed solvent of DCE (70 mL) and DMF (70 mL) was stirred for 4 hrs at 90°C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure and then diluted with water (200 mL). The aqueous layer was extracted with EtOAc (300 mL x 2). The combined organic phase was dried over anhydrous Na2SO4and concentrated in vacuum to give the crude product, which was directly purified by flash chromatography (PE : THF = 3:1 (v / v)) mixture to give ethyl 2-chloro-4-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]1,8- naphthyridine-8-carboxylate (A) (7.2 g, 52.79%) as a yellow solid. MS (ESI, m / z): calcd. for C15H9ClF5N3O2: 393.0; Found: 394.1 [M + 1]+.1H NMR (400 MHz, CDCl3): δ 9.08 (s, 1H), 7.86 (d, J = 10.0 Hz, 1H), 7.80 (d, J = 10.0 Hz, 1H), 7.77 (s, 1H), 4.51 (q, J = 7.1 Hz, 2H), 1.48 (t, J = 7.1 Hz, 3H) ppm. Intermediate B: ethyl 4-chloro-2-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]1,8-naphthyridine-8- carboxylate Step 1. Synthesis of 7-amino-2-(1,1,2,2,2-pentafluoroethyl)-1H-1,8-naphthyridin-4-one (B- 2). A solution of 2,6-diaminopyridine (B-1) (10 g, 91.63 mmol) and ethyl 4,4,5,5,5-pentafluoro- 3-oxopentanoate (30.03 g, 128.29 mmol) in concd. sulfuric acid (300 mL) was stirred for 80 °C at 16 hrs under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (300 mL) and neutralized to pH 8-9 with Sat. NaHCO3 (aq). The formed yellow solids were collected by filtration, washed with H2O (300 mL) and dried over air to give 7-amino-2-(1,1,2,2,2-pentafluoroethyl)-1H-1,8-naphthyridin- 4-one (B-2) (11 g, 43.00%) as a yellow solid. MS (ESI, m / z): calcd. for C10H6F5N3O: 279.0; Found: 280.1 [M + 1]+. Step 2. Synthesis of ethyl 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2-a]1,8- naphthyridine-8-carboxylate (B-3). A solution of 7-amino-2-(1,1,2,2,2-pentafluoroethyl)-1H- 1,8-naphthyridin-4-one (B-2) (11.00 g, 39.40 mmol) and ethyl 3-bromo-2-oxopropanoate (15.37 g, 78.806 mmol) in THF (110 mL) was stirred at 70 °C for 10 hrs under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (110 mL). The aqueous layer was extracted with EA (110 mL x 3) and the combined organic phase was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with (PE: THF = 1:10 (v / v)) to give ethyl 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2- a]1,8-naphthyridine-8-carboxylate (B-3) (9.5 g, 64.25%) as a yellow solid. MS (ESI, m / z): calcd. for C15H10F5N3O3: 375.0; Found: 376.1 [M + 1]+. Step 3. Synthesis of ethyl 4-chloro-2-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]1,8- naphthyridine-8-carboxylate (B). A solution of ethyl 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H- imidazo[1,2-a]1,8-naphthyridine-8-carboxylate (B-3) (9.50 g, 25.32 mmol) and phosphorus oxychloride (19.41 g, 126.58 mmol) in a mixed solvent of DMF (50 mL) and DCE (50 mL) was stirred at 90 °C for 4 hrs under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (100 mL) and the aqueous layer was extracted with EA (100 mL x 3). The combined organic phase was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography, eluted with (EA:PE =1:2 (v / v)), to give ethyl 4-chloro-2-(1,1,2,2,2- pentafluoroethyl)imidazo[1,2-a]1,8-naphthyridine-8-carboxylate (B) (7.3 g, 73.24%) as a yellow solid. MS (ESI, m / z): calcd. for C15H9ClF5N3O2: 393.0; Found: 394.1 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 8.82 (s, 1H), 8.50 (s, 1H), 8.06-8.03 (d, J = 9.9 Hz, 1H), 7.99-7.95 (d, J = 9.9 Hz, 1H), 4.38 (q, J = 7.2 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H) ppm. Intermediate C (method 1): 2-(4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole Step 1. Synthesis of 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2-a]1,8- naphthyridine-8-carbohydrazide (C-1). A solution of ethyl 4-oxo-2-(1,1,2,2,2- pentafluoroethyl)-1H-imidazo[1,2-a]1,8-naphthyridine-8-carboxylate (B-3) (1.50 g, 4.00 mmol) and hydrazine (1.5 mL) in EtOH (15 mL) was stirred for 70°C at 4h under nitrogen atmosphere. The mixture was allowed to cool down to rt and was concentrated under reduced pressure. The residue was purified by reversed-phase flash column chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water, 10% to 30% gradient over 15 min; detector, UV 254 nm to give 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2-a]1,8- naphthyridine-8-carbohydrazide (C-1) (0.5 g, 34.63%) as a yellow solid. MS (ESI, m / z): calcd. for C13H8F5N5O2: 361.0; Found: 362.1 [M + 1]+. Step 2. Synthesis of 8-(1,3,4-oxadiazol-2-yl)-2-(1,1,2,2,2-pentafluoroethyl)-1H-imidazo[1,2- a]1,8-naphthyridin-4-one (C-2). A solution of 4-oxo-2-(1,1,2,2,2-pentafluoroethyl)-1H- imidazo[1,2-a]1,8-naphthyridine-8-carbohydrazide (C-1) (500 mg, 1.38 mmol) and p- toluenesulfonic acid (357.53 mg, 2.08 mmol) in trimethyl orthoformate (5 mL) was stirred for 70 °C at 4h under nitrogen atmosphere. The mixture was allowed to cool down to rt and was diluted with H2O (30 mL). The mixture was extracted with EA (30 mL x 3) and the combined organic phase was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE: THF (1:1 (v / v)) to give 8-(1,3,4-oxadiazol-2-yl)-2-(1,1,2,2,2-pentafluoroethyl)-1H- imidazo[1,2-a]1,8-naphthyridin-4-one (C-2) (200 mg, 38.92%) as a brown solid. MS (ESI, m / z): calcd. for C14H6F5N5O2: 371.0; Found: 372.1 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.39 (s, 1H), 8.87 (s, 1H), 8.00 ‒ 7.97 (d, J = 9.9 Hz, 1H), 7.73 ‒ 7.70 (d, J = 9.9 Hz, 1H), 7.32 (s, 1H) ppm. Step 3. Synthesis of 2-[4-chloro-2-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]1,8- naphthyridin-8-yl]-1,3,4-oxadiazole (C). A solution of 8-(1,3,4-oxadiazol-2-yl)-2-(1,1,2,2,2- pentafluoroethyl)-1H-imidazo[1,2-a]1,8-naphthyridin-4-one (C-2) (200 mg, 0.54 mmol) and phosphorus oxychloride (413.01 mg, 2.70 mmol) in dimethylformamide (2 mL) and DCE (2 mL) was stirred for 4hr at 90 °C under nitrogen atmosphere. The mixture was allowed to cool to rt and the solvent was removed under reduced pressure. The residue was purified by reversed- phase flash column chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water, 20% to 60% gradient in 10 min; detector, UV 254 nm to give 2- [4-chloro-2-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole (C) (20 mg, 9.53%) as a white solid. MS (ESI, m / z): calcd. for C13H8F5N5OCl: 389.0; Found: 390.1 [M + 1]+. Intermediate C (method 2): 2-(4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole Step 1. Synthesis of 4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8- carboxylic acid (C-4). To a stirred solution of ethyl 4-chloro-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (B) (3.0 g, 7.62 mmol) in anhydrous DCM (90 mL) was added 1 M BBr3 / DCM (76.22 mL, 76.20 mmol) at room temperature and stirred for 3 h. The reaction progress was monitored by LCMS. After completion of reaction, the reaction mixture was concentrated under reduced pressure to give crude product which was poured into ice water (150 mL), the solid was filtered and the filter cake was dried to give the desired product 4- chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid (C-4) (1.70 g, 61.01%) as a white solid. MS (ESI, m / z): calcd. for C13H5ClF5N3O2: 365.0; Found: 366.0 [M+1]+. Step 2. Synthesis of 2-(4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole (C). To a stirred solution of 4-chloro-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylic acid (C-4) (1.50 g, 4.10 mmol) in anhydrous toluene (50 mL) was added isocyano(triphenyl-lambda5-phosphanylidene)amine (1.86 g, 6.15 mmol), and the reaction mixture was stirred at 80°C for 3 h under nitrogen atmosphere. The reaction progress was monitored by LCMS. After completion of reaction, the reaction mixture was concentrated under reduced pressure to give crude product which was further purified by column chromatography using PE / EA = 3:1 to 1:1 (v / v) gradient to give desired compound 2-(4-chloro- 2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (C) (900 mg, 56.30%) as a white solid. MS (ESI, m / z): calcd. for C14H5ClF5N5O: 389.0; Found: 390.0 [M+1]+. II. General procedure for synthesis of 4-aromatic compounds. Method 1: Synthesis of 4-aromatic compounds using intermediate B. Step 1 method 1. Synthesis of D-1. To a stirred mixture of ethyl 4-chloro-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (B) (130 mg, 0.33 mmol) and corresponding boronic ester or acid (0.50 mmol) in dioxane / H2O (10 / 1 mL) were added Pd(dppf)Cl2(24.20 mg, 0.033 mmol) and K2CO3(137.15 mg, 0.99 mmol) under N2atmosphere. The mixture was stirred for 3 h at 100°C under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (15 mL) and the mixture was extracted with EA (3 x 30 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with THF / PE to give compound D-1. Step 1 method 2. Synthesis of D-1. To a stirred mixture of ethyl 4-chloro-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (B) (130 mg, 0.33 mmol) and corresponding tin reagent R-Sn(Me)3(0.99 mmol) in toluene (10 mL) were added Pd(PPh3)4(38.1 mg, 0.033 mmol) under N2 atmosphere. The mixture was stirred for 3 h at 100°C under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with THF / PE to give compound D-1. Step 2. Synthesis of D-2. A solution of compound D-1 obtained above and NH2NH2•H2O (0.2 mL) in EtOH (2.0 mL) was stirred for 8 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to give compound D-2. Step 3. Synthesis of D. A solution of compound D-2 obtained above and TsOH (17 mg, 0.10 mmol) in CH(OMe)3(2 mL) was stirred for 4 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to give compound D. Method 2: Synthesis of 4-aromatic compounds using intermediate C. A mixture of 2-(4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (C) (80.00 mg, 0.21 mmol), boronic ester or boronic acid (0.31 mmol), K2CO3(85.74 mg, 0.61 mmol) and Pd(dppf)Cl2(15 mg, 0.02 mmol) in dioxane (4 mL) and water (0.4 mL) was stirred for 3 h at 100 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (10 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (20% ACN up to 95% in 5 min) to give compound D. Example 1. 2-(4-(Perfluoroethyl)-2-phenylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole CF2CF3CF2CF3CF2CF3N N Step 1. Synthesis of ethyl 4-(perfluoroethyl)-2-phenylimidazo[1,2-a][1,8]naphthyridine-8- carboxylate (1-1). To a stirred solution of ethyl 2-chloro-4-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (A) (0.40 g, 1.02 mmol) in 1, 4-dioxane and water (4:0.4 mL) were added compound phenylboronic acid (0.15 g, 1.22 mmol) and K3PO4 (0.43 g, 2.03 mmol) and the reaction mixture was purged under nitrogen for 10 min. To the reaction solution, Pd(dppf)Cl2(74.34 mg, 0.10 mmol) was added under nitrogen atmosphere. The reaction mixture was heated at 90 °C for 4 h. After completion of the reaction, the reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water (10 mL) and extracted with EtOAc (30mL x 3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (using a gradient method of 70-80% EtOAc in heptane) to give ethyl 4-(perfluoroethyl)-2-phenylimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (1-1) (0.32 g, 72.72%) as an off-white solid. TLC: 80% EtOAc / Heptane (Rf: 0.5). MS (ESI, m / z): calcd. for C21H14F5N3O2: 435.10; Found: 436.2 [M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 9.25 (s, 1H), 8.50 (s, 3H), 7.89 (d, J = 9.3 Hz, 1H), 7.86- 7.81 (m, 1H), 7.61 (s, 3H), 4.38 (q, J = 6.9 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H) ppm. Step 2. Synthesis of 4-(perfluoroethyl)-2-phenylimidazo[1,2-a][1,8]naphthyridine-8- carbohydrazide (1-2). To a stirred solution of ethyl 4-(perfluoroethyl)-2-phenylimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (1-1) (0.35 g, 0.80 mmol) in ethanol (10 mL) was added hydrazine hydrate (0.30 g, 9.66 mmol) and the reaction mixture was stirred at 80 °C for 4 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to give 4-(perfluoroethyl)-2- phenylimidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (1-2) (0.3 g, crude) as a yellow solid. TLC: 70% EtOAc in heptane (Rf: 0.5). MS (ESI, m / z): calcd. for C19H12F5N5O: 421.10; Found: 421.9 [M + 1]+. Step 3. Synthesis of 2-(4-(perfluoroethyl)-2-phenylimidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole (Example 1). To a stirred solution of 4-(perfluoroethyl)-2-phenylimidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (1-2) (0.3 g, 0.71 mmol) in triethyl orthoformate (5 mL) was added TsOH (94.62 mg, 0.55 mmol) and the reaction mixture was then stirred at 110 °C for 16 h. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5.0 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 1-2% MeOH in DCM to give 2-(4-(perfluoroethyl)-2-phenylimidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole (Example 1) (35 mg, 11.40%) as an off-white solid. TLC: 5% MeOH in DCM (Rf: 0.5). MS (ESI, m / z): calcd. for C20H10F5N5O: 431.08; Found: 432.0 [M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 9.55 (s, 1H), 9.44 (s, 1H), 8.62 - 8.58 (m, 2H), 8.56 (s, 1H), 7.98 - 7.90 (m, 2H), 7.66 - 7.60 (m, 3H) ppm. Table 1 shows structure and analytical data for representative Example of the present invention. The compound can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 1: Analytical data of representative compound Example Structure MS [M + 1]+ 1H NMR 1H NMR (400 MHz, DMSO-d6): δ 9.78 (s, = ), Example 3. 2-(2-(Perfluoroethyl)-4-phenylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole Step 1. Synthesis of ethyl 2-(perfluoroethyl)-4-phenylimidazo[1,2-a][1,8]naphthyridine-8- carboxylate (3-1). To a stirred solution of ethyl 4-chloro-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (B) (0.3 g, 0.76 mmol) in 1, 4-dioxane and water (3:0.5 mL) were added phenylboronic acid (0.11 g, 0.92 mmol) and K3PO4(0.32 g, 1.53 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting solution, PdCl2(dppf) (53 mg, 0.076 mmol) was added under nitrogen atmosphere. The reaction mixture was heated at 90 °C for 6 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 50-60% EtOAc in heptane) to give ethyl 2-(perfluoroethyl)-4- phenylimidazo[1,2-a][1,8]naphthyridine-8-carboxylate (3-1) (0.25 g, 75.75%) as an off-white solid. TLC: 80% EtOAc / Heptane (Rf: 0.5). MS (ESI, m / z): calcd. for C21H14F5N3O2: 435.10; Found: 436.31 [M + 1]+. Step 2. Synthesis of 2-(perfluoroethyl)-4-phenylimidazo[1,2-a][1,8]naphthyridine-8- carbohydrazide (3-2). To a stirred solution of ethyl 2-(perfluoroethyl)-4-phenylimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (3-1) (0.10 g, 0.23 mmol) in ethanol (2 mL) was added hydrazine hydrate (2 mL) and the reaction mixture was stirred at 90 °C for 2 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to give the title compound 2-(perfluoroethyl)-4- phenylimidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (3-2) (0.30 g, crude) as a yellow solid. TLC: 70% EtOAc in heptane (Rf: 0.5). MS (ESI, m / z): calcd. for C19H12F5N5O: 421.10; Found: 422.56 [M + 1]+. Step 3. Synthesis of 2-(2-(perfluoroethyl)-4-phenylimidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole (Example 3). To a stirred solution of 2-(perfluoroethyl)-4-phenylimidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (3-2) (0.10 g, 0.24 mmol) in triethyl orthoformate (12 mL) was added TsOH (40.60 mg, 0.24 mmol) and the reaction mixture was then stirred at 120 °C for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5.0 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with water, dried over anhydrous Na2SO4,filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 50-80% EtOAc in heptane to give 2-(2-(perfluoroethyl)-4-phenylimidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 3) (88 mg, 29.33%) as an off-white solid. TLC: 60% EtOAc in heptane (Rf: 0.5). MS (ESI, m / z): calcd. for C20H10F5N5O: 431.08; Found: 432.0 [M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.07 (s, 1H), 8.14 (s, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.76 (d, J = 9.3 Hz, 1H), 7.71 - 7.61 (m, 5H) ppm. Table 2 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. The stereochemistry of these pure enantiomers was arbitrarily assigned. Table 2: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR N 0 , 1H NMR (400 MHz, DMSO-d6): δ 9.42 (s, , = = s, 1 J 5 3 1H NMR (400 MHz, DMSO-d6): δ 10.09 (s, ), - 1 s, ), d, d, , 1H NMR (400 MHz, DMSO-d6): δ 9.42 (s, 8 - 2 1 = 1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, J 1 , = ), ), 1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, 8 z, ) m, 1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, ), s, , ) ) = – O1H NMR (300 MHz, Methanol-d4): δ 9.22 (s, – , - 1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, N 1H), 9.07 (s, 1H), 8.93 (d, J = 4.2 Hz, 1H), 8 1 ) m, z, – 1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.08 (s, 1H), 8.22 (m, 1H), 8.20 (m, , , z, , z, 1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, , t, ), ) 1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, = - 5 - 9 z, 9 = 1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, s, s, 4 m 476.1 1H NMR (400 MHz, DMSO-d6): δ 9.43 (s,, = , , 9 1H NMR (300 MHz, DMSO-d6): δ 9.44 (s, , t, 1 = 0 1H NMR (300 MHz, DMSO-d6): δ 9.44 , s, z, 7 , , ), 1H NMR (300 MHz, DMSO-d6): δ 9.99 (s, ), (t, 5 , , 8 , 1HNMR (400 MHz, CDCl3): δ 9.27 (s, 1H), s, 3 s, , .9 9 1 - , 1H NMR (400 MHz, DMSO-d6): δ 9.42 (s, , = t, - - 1 1H NMR (300 MHz, DMSO-d6): δ 9.44 (s, = , ), 1H NMR (300 MHz, DMSO-d6): δ 9.44 (s, , , 7 xamp e . - - - - uoropropan- -y p eny - - per uoroe y m azo[ ,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Step 1. Synthesis of ethyl 4-(4-(2-fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (103-2). To a solution of ethyl 4-(4-(2-hydroxypropan-2- yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (103-1) (110 mg, 0.22 mmol) in DCM (2.0 mL) at -78°C under nitrogen atmosphere was added DAST (41.34 mg, 1.12 mmol).The resulting mixture was stirred at -78°C under nitrogen atmosphere for 1 h. The reaction was monitored by LCMS. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with DCM (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:2 (v / v)) to give ethyl 4-(4- (2-fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (103-2) (110 mg, 99.60%) as a yellow oil. MS (ESI, m / z): calcd. for C24H19F6N3O2: 495.1; Found: 496.2 [M + 1]+. Step 2. Synthesis of 4-(4-(2-fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (103-3). A solution of ethyl 4-(4-(2-fluoropropan-2- yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (103-2) (110 mg, 0.22 mmol) and NH2NH2•H2O (0.2 mL) in EtOH (2.0 mL) was stirred at 70°C under nitrogen atmosphere for 4 h. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature and was concentrated under reduced pressure to give 4-(4-(2-fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (103-3) (100 mg, 93.56%) as a yellow oil. MS (ESI, m / z): calcd. for C15H7F8N3O: 481.1; Found: 482.2 [M + 1]+. Step 3. Synthesis of 2-(4-(4-(2-fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 103). A solution of 4-(4-(2- fluoropropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (103-3) (100 mg, 0.21 mmol) and TsOH (17.89 mg, 0.10 mmol) in CH(OMe)3(2 mL) was stirred at 70°C under nitrogen atmosphere for 4 h. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (10 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (20% Phase B to 70% in 12 min); Detector, UV 254 nm, to give 2-(4-(4-(2-fluoropropan- 2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 103) (28.5 mg, 27.92%) as a white solid. MS (ESI, m / z): calcd. for C23H15F6N5O: 491.1; Found: 492.2 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, 1H), 9.05 (s, 1H), 8.15 (s, 1H), 7.89 (d, J = 9.9 Hz, 1H), 7.77 (d, J = 9.9 Hz, 1H), 7.70 (s, 4H), 1.75 (d, J = 22.2 Hz, 6H) ppm. Example 104. 2-(4-(4-(2-Methoxypropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole

[0002] Synthesis of 2-(4-(4-(2-methoxypropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 104). A solution of 4-(4-(2- hydroxypropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8- carbohydrazide (104-1) (90 mg, 0.19 mmol) and TsOH (16.16 mg, 0.094 mmol) in CH(OMe)3(2 mL) was stirred for 4 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (10 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (20% Phase B to 70% in 12 min); Detector, UV 254 nm, to give 2-(4-(4-(2- methoxypropan-2-yl)phenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (Example 104) (10.5 mg, 11.11%) as a white solid. MS (ESI, m / z): calcd. for C24H18F5N5O2: 503.1; Found: 504.2 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, 1H), 9.05 (s, 1H), 8.15 (s, 1H), 7.91 (d, J = 9.9 Hz, 1H), 7.79 (d, J = 9.9 Hz, 1H), 7.67 (s, 4H), 3.09 (s, 3H), 1.54 (s, 6H) ppm. Example 105. 2-(4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin- 4-yl)phenyl)propan-2-ol Synthesis of 2-(4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)phenyl)propan-2-ol (Example 105). A solution of 1-(4-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)ethan-1-one (105-1) (18.00 mg, 0.03 mmol) and MeMgBr (9.07 mg, 0.07 mmol) in THF (2 mL) was stirred for 2 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was quenched with H2O (10 mL). The aqueous layer was extracted with EA (30 mL x 3) and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water, 30% to 90% gradient in 9 min; detector, UV 254 nm, to give 2-(4-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)propan-2-ol (Example 105) (6.10 mg, 32.78%) as a white solid. MS (ESI, m / z): calcd. for C23H16F5N5O2: 489.1; Found: 490.2 [M + 1]+.1H NMR (300 MHz, CDCl3): δ 9.28 (s, 1H), 8.56 (s, 1H), 7.86 (s, 1H), 7.80 (m, 4H), 7.52 (d, J = 8.1 Hz, 2H), 1.68 (s, 6H) ppm. Example 106. (4-(8-(1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)phenyl)methanol Step 1. Synthesis of 7-amino-2-(trifluoromethyl)-1,8-naphthyridin-4(1H)-one (106-2). A solution of ethyl 4,4,4-trifluoro-3-oxobutanoate (106-1) (15.18 g, 82.47 mmol) and 2,6- diaminopyridine (6 g, 54.98 mmol) in H2SO4(concd. 60 mL) was stirred for 6 h at 80°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature and then diluted with H2O (200 mL). The mixture was basified to pH = 8 with Sat. NaHCO3 (aq.). The precipitated solids were collected by filtration and washed with H2O (100 mL). This resulted in 7-amino-2- (trifluoromethyl)-1,8-naphthyridin-4(1H)-one (106-2) (1.20 g, 9.52%) as a yellow solid. MS (ESI, m / z): calcd. for C9H6F3N3O: 229.0; Found: 230.0 [M + 1]+. Step 2. Synthesis of ethyl 4-oxo-2-(trifluoromethyl)-1,4-dihydroimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (106-3). A solution of 7-amino-2-(trifluoromethyl)-1,8- naphthyridin-4(1H)-one (106-2) (1.2 g, 5.24 mmol) and NaHCO3 (1.32 g, 15.71 mmol), ethyl 3- bromo-2-oxopropanoate (1.53 g, 7.85 mmol) in THF (20 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (100 mL). The precipitated solids were collected by filtration and washed with H2O (100 mL). This resulted in ethyl 4-oxo-2-(trifluoromethyl)-1,4- dihydroimidazo[1,2-a][1,8]naphthyridine-8-carboxylate (106-3) (900 mg, 52.84%) as a yellow solid. MS (ESI, m / z): calcd. for C14H10F3N3O3: 325.1; Found:326.0 [M + 1]+. Step 3. Synthesis of ethyl 4-chloro-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8- carboxylate (106-4). A solution of ethyl 4-oxo-2-(trifluoromethyl)-1,4-dihydroimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (106-3) (900 mg, 2.77 mmol) and POCl3(2121.28 mg, 13.84 mmol) in DCE (5 mL) and DMF (10 mL) was stirred for 4 h at 90°C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (100 mL). The precipitated solids were collected by filtration and washed with H2O (100 mL). This resulted in ethyl 4-chloro-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8- carboxylate (106-4) (400.00 mg, 42.06%) as a yellow solid. MS (ESI, m / z): calcd. for C14H9ClF3N3O2: 343.0; Found: 344.0 [M + 1]+. Step 4. Synthesis of ethyl 4-(4-(hydroxymethyl)phenyl)-2-(trifluoromethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (106-5). A solution of ethyl 4-chloro-2- (trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (400.00 mg, 1.16 mmol) and (4-(hydroxymethyl)phenyl)boronic acid (106-4) (265.29 mg, 1.75 mmol), K2CO3 (321.70 mg, 2.33 mmol), Pd(dppf)Cl2(42.58 mg, 0.058 mmol) in dioxane (4 mL) was stirred for 3 h at 100°C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (20 mL) and the mixture was extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:1 (v / v)) to give ethyl 4-(4-(hydroxymethyl)phenyl)-2- (trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (106-5) (290.00 mg, 59.99%) as a yellow solid. MS (ESI, m / z): calcd. for C21H16F3N3O3: 415.1; Found: 416.1 [M + 1]+. Step 5. Synthesis of 4-(4-(hydroxymethyl)phenyl)-2-(trifluoromethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (106-6). A solution of ethyl 4-(4- (hydroxymethyl)phenyl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (106-5) (290.00 mg, 0.7 mmol) and NH2NH2•H2O (0.6 mL) in EtOH (6 mL) was stirred for 3 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. This resulted in 4-(4-(hydroxymethyl)phenyl)-2- (trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (106-6) (190.00 mg, 67.81%) as a yellow solid. MS (ESI, m / z): calcd. for C19H14F3N5O2: 401.1; Found: 402.1 [M + 1]+. Step 6. Synthesis of (4-(8-(1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 106). A solution of 4-(4- (hydroxymethyl)phenyl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (106-6) (100.00 mg, 0.25 mmol) and TsOH (21.45 mg, 0.12 mmol) in CH(OMe)3(2 mL) was stirred for 4 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (30 mL) and the mixture was extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (30% Phase B to 90% in 10 min); detector, UV 254 nm, to give (4-(8-(1,3,4-oxadiazol-2- yl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 106) (7.4 mg, 7.22%) as a white solid. MS (ESI, m / z): calcd. for C20H12F3N5O2: 411.1; Found: 412.1[M + 1]+.1H NMR (300 MHz, Acetonitrile-d3): δ 9.14 (s, 1H), 8.76 (s, 1H), 7.98 (s, 1H), 7.80 (d, J = 9.9 Hz, 1H), 7.71 (d, J = 9.9 Hz, 1H), 7.64 – 7.57 (m, 4H), 4.75 (s, 2H) ppm. Example 107. 2-(4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole

[0003] Cl Br Br 3 Step 1. Synthesis of ethyl 4-bromo-2-(cyclobut-1-en-1-yl)imidazo[1,2-a][1,8]naphthyridine- 8-carboxylate (107-2). A mixture of ethyl 2,4-dibromoimidazo[1,2-a]1,8-naphthyridine-8- carboxylate (107-1) (400.00 mg, 1.00 mmol), 2-(cyclobut-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane (180.00 mg, 1.00 mmol), Pd(dppf)Cl2(40.85 mg, 0.05 mmol) and Na2CO3(214.51 mg, 2.00 mmol) in dioxane / H2O (15 mL / 1.5 mL) was stirred for 8 h at 80 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (20 mL) and the resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (3:1 (v / v)) to give ethyl 4-bromo-2-(cyclobut-1-en-1- yl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (107-2) (170.00 mg, 45.56%) as a light yellow solid. MS (ESI, m / z): calcd. for C17H14BrN3O2: 371.0; Found: 373.0[M+1]+.1H NMR (300 MHz, CDCl3): δ 9.13 – 9.03 (m, 1H), 7.87 (d, J = 9.9 Hz, 1H), 7.75 (s, 1H), 7.67 (d, J = 9.9 Hz, 1H), 6.89 (d, J = 1.5 Hz, 1H), 4.52 (q, J = 7.2 Hz, 2H), 3.09 – 2.92 (m, 2H), 2.75 – 2.66 (m, 2H), 1.50 (t, J = 7.2 Hz, 3H) ppm. Step 2. Synthesis of ethyl 4-(4-chlorophenyl)-2-(cyclobut-1-en-1-yl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (107-3). A mixture of ethyl 4-bromo-2-(cyclobut-1-en-1- yl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (107-2) (170.00 mg, 0.45 mmol), (4- chlorophenyl)boronic acid (142.83 mg, 0.91 mmol), Pd(dppf)Cl2(33.42 mg, 0.04 mmol) and K2CO3 (190.74 mg, 1.37 mmol) in dioxane / H2O (10 / 1 mL) was stirred for 2 h at 100 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (20 mL) and the mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (3:1) to give ethyl 4-(4-chlorophenyl)-2-(cyclobut-1-en- 1-yl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (107-3) (80.00 mg, 43.37%) as a light yellow solid. MS (ESI, m / z): calcd. for C23H18ClN3O2: 403.1; Found: 404.0 [M+1]+.1H NMR (300 MHz, CDCl3): δ 9.16 (s, 1H), 7.62 – 7.50 (m, 4H), 7.46 – 7.41 (m, 3H), 6.87 (s, 1H), 4.52 (q, J = 7.2 Hz, 2H), 3.11 – 2.98 (m, 2H), 2.78 – 2.60 (m, 2H), 1.50 (t, J = 7.2 Hz, 3H) ppm. Step 3. Synthesis of ethyl 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2-a][1,8]naphthyridine- 8-carboxylate (107-4). A mixture of ethyl 4-(4-chlorophenyl)-2-(cyclobut-1-en-1- yl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (107-3) (80.00 mg, 0.19 mmol) and Pd / C (4.00 mg, 0.04 mmol) in EtOAc (20 mL) was stirred for 2 h at room temperature under hydrogen atmosphere. After completion of the reaction, the resulting mixture was filtered, the filter cake was washed with EtOAc (20 mL x 3). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (2:1 (v / v)) to give ethyl 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (107-4) (70.00 mg, 87.07%) as an off-white solid. MS (ESI, m / z): calcd. for C23H20ClN3O2: 405.1; Found: 406.0 [M+1]+.1H NMR (300 MHz, CDCl3): δ 9.23 (s, 1H), 7.70 (q, J = 9.9 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.1 Hz, 2H), 7.31 (s, 1H), 4.59 – 4.51 (m, 2H), 3.95 – 3.84 (m, 1H), 2.63 – 2.47 (m, 4H), 2.30 – 2.04 (m, 2H), 1.52 (t, J = 7.2 Hz, 3H) ppm. Step 4. Synthesis of 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2-a][1,8]naphthyridine-8- carbohydrazide (107-5). A mixture of ethyl 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2- a][1,8]naphthyridine-8-carboxylate (107-4) (70.00 mg, 0.17 mmol) and NH2NH2·H2O (172.68 mg, 3.44 mmol) in EtOH (4 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (5 mL) and the mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2-a][1,8]naphthyridine-8- carbohydrazide (107-5) (70.00 mg, 103.58%) as an off-white solid. The crude product was used in the next step directly without further purification. MS (ESI, m / z): calcd. for C21H18ClN5O: 391.1; Found: 392.0 [M+1]+. Step 5. Synthesis of 2-(4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2-a][1,8]naphthyridin-8- yl)-1,3,4-oxadiazole (Example 107). A mixture of 4-(4-chlorophenyl)-2-cyclobutylimidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (107-5) (70.00 mg, 0.18 mmol) and TsOH (15.38 mg, 0.09 mmol) in CH(OMe)3(5 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (20% ACN up to 95% in 5 min) to give 2-(4-(4-chlorophenyl)-2- cyclobutylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 107) (20.00 mg, 27.86%) as an off-white solid. MS (ESI, m / z): calcd. for C22H16ClN5O: 401.1; Found: 402.1 [M+1]+.1H NMR (300 MHz, DMSO-d6): δ 9.41 (s, 1H), 9.22 (s, 1H), 7.71 – 7.62 (m, 6H), 7.54 (s, 1H), 3.98 – 3.92 (m, 1H), 2.56 – 2.50 (m, 2H), 2.47 – 2.39 (m, 2H), 2.16 – 1.98 (m, 2H) ppm. Example 108. 2-(4-(4-Chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2-a][1,8]naphthyridin-8- yl)-1,3,4-oxadiazole

[0004] Step 1. Synthesis of ethyl 4-(4-chlorophenyl)-2-(1-hydroxycyclobutyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (108-1). To a stirred solution of ethyl 4-(4-chlorophenyl)- 2-(cyclobut-1-en-1-yl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (107-3) (70.00 mg, 0.17 mmol) and Mn(Dpm)3(31.44 mg, 0.05 mmol) in i-PrOH (13 mL) was added phenylsilane (93.78 mg, 0.86 mmol) dropwise at -10 °C under O2atmosphere. The resulting mixture was stirred for 10 h at -10 °C. After completion of the reaction, the reaction was quenched by the addition of sat. NaHCO3(aq.) (10 mL) at room temperature. The resulting mixture was extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 2 / 1 (v / v) to give ethyl 4-(4-chlorophenyl)-2-(1-hydroxycyclobutyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (108-1) (40.00 mg, 54.70%) as an off-white solid. MS (ESI, m / z): calcd. for C23H20ClN3O3: 421.1; Found: 422.0 [M+1]+. Step 2. Synthesis of ethyl 4-(4-chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (108-2). To a stirred solution of ethyl 4-(4-chlorophenyl)- 2-(1-hydroxycyclobutyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (108-1) (40.00 mg, 0.09 mmol) in DCM (10 mL) was added DAST (10.55 mg, 0.28 mmol) dropwise at - 78 °C under nitrogen atmosphere. The resulting mixture was stirred for 4 h and slowly warmed to room temperature. After completion of the reaction, the reaction was quenched by the addition of sat. NaHCO3(aq.) (10 mL) at room temperature. The resulting mixture was extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 3 / 1 (v / v) to give ethyl 4-(4-chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (108-2) (35.00 mg, 87.09%) as an off-white solid. MS (ESI, m / z): calcd. for C23H19ClFN3O2: 423.1; Found: 424.1 [M+1]+.1H NMR (300 MHz, CDCl3): δ 9.16 (s, 1H), 7.66 (d, J = 1.5 Hz, 1H), 7.63 (s, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.49 – 7.42 (m, 2H), 4.55 (q, J = 7.2 Hz, 2H), 3.08 – 3.05 (m, 3H), 3.00 – 2.56 (m, 2H), 2.28 – 2.20 (m, 1H), 1.52 (t, J = 7.2 Hz, 3H) ppm. Step 3. Synthesis of 4-(4-chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (108-3). A mixture of ethyl 4-(4-chlorophenyl)-2-(1- fluorocyclobutyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (108-2) (35.00 mg, 0.08 mmol) and NH2NH2·H2O (82.67 mg, 1.66 mmol) in EtOH (2 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (5 mL) and the mixture was extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product of 4-(4-chlorophenyl)-2-(1- fluorocyclobutyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (108-3) was used in the next step directly without further purification. MS (ESI, m / z): calcd. for C21H17ClFN5O: 409.1; Found: 410.2 [M+1]+. Step 4. Synthesis of 2-(4-(4-chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 108). A mixture of 4-(4-chlorophenyl)-2- (1-fluorocyclobutyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (108-3) (35.00 mg, 0.08 mmol) and TsOH (7.35 mg, 0.04 mmol) in CH(OMe)3(2 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% NH3·H2O) and ACN (20% ACN up to 95% in 5 min) to give 2-(4-(4-chlorophenyl)-2-(1-fluorocyclobutyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 108) (5.00 mg, 13.95%) as an off- white solid. MS (ESI, m / z): calcd. for C22H15ClFN5O: 419.1; Found: 420.1 [M+1]+.1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, 1H), 9.28 (s, 1H), 7.78 – 7.75 (m, 1H), 7.72 – 7.55 (m, 6H), 2.96 – 2.92 (m, 2H), 2.78 – 2.60 (m, 2H), 2.30 – 2.11 (m, 2H) ppm. Example 109. 5-(4-(4-Chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8- yl)oxazole Step 1. Synthesis of 4-chloro-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8- carbaldehyde (109-1). To a stirred solution of ethyl 4-chloro-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (B) (200.00 mg, 0.51 mmol) in DCM (20 mL) was added DIBAL-H (361.24 mg, 2.54 mmol) in DCM (10 mL) dropwise at - 78 °C under nitrogen atmosphere. The resulting mixture was stirred for 1 h at -78 °C. After completion of the reaction, the reaction was quenched by Na2SO4·10H2O (100.00 mg) at 0 °C. The resulting mixture was filtered, and the filter cake was washed with DCM (10 mL x 3). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF =3 / 1 (v / v) to give 4-chloro-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbaldehyde (109-1) (75.00 mg, 42.22%) as an off-white solid. MS (ESI, m / z): calcd. for C13H5ClF5N3O: 349.0; Found: 350.1 [M+1]+.1H NMR (300 MHz, CDCl3): δ 10.25 (s, 1H), 9.10 (s, 1H), 8.05 (d, J = 9.9 Hz, 1H), 8.00 (s, 1H), 7.90 (d, J = 9.9 Hz, 1H) ppm. Step 2. Synthesis of 4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine- 8-carbaldehyde (109-2). A mixture of 4-chloro-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbaldehyde (109-1) (75.00 mg, 0.22 mmol), (4-chlorophenyl)boronic acid (67.08 mg, 0.43 mmol), Pd(dppf)Cl2(15.70 mg, 0.02 mmol) and K2CO3(88.94 mg, 0.65 mmol) in dioxane / H2O (3 / 0.3 mL) was stirred for 3 h at 100 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (10 mL) and was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 2 / 1 (v / v) to give 4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbaldehyde (109-2) (50.00 mg, 54.75%) as an off-white solid. MS (ESI, m / z): calcd. for C19H9ClF5N3O: 425.0; Found: 425.9 [M+1]+. Step 3. Synthesis of 5-(4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)oxazole (Example 109). A mixture of 4-(4-chlorophenyl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbaldehyde (109-2) (50.00 mg, 0.12 mmol), TosMIC (25.22 mg, 0.13 mmol) and K2CO3 (17.98 mg, 0.13 mmol) in MeOH (3 mL) was stirred for 4 h at 65 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (5 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (20% ACN up to 95% in 5 min) to give 5-(4-(4-chlorophenyl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)oxazole (Example 109) (5.00 mg, 9.16%) as a light yellow solid. MS (ESI, m / z): calcd. for C21H10ClF5N4O: 464.0; Found: 465.1 [M+1]+.1H NMR (300 MHz, DMSO-d6): δ 8.79 (s, 1H), 8.53 (s, 1H), 8.10 (s, 1H), 7.84 (d, J = 9.9 Hz, 1H), 7.75 – 7.66 (m, 6H) ppm. Table 3 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 3: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR ), 1 ), 7 Example 112. (4-(4-Chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methanol

[0005] Step 1. Synthesis of ethyl 4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (112-1). A solution of ethyl 4-chloro-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (B) (1.05 g, 2.67 mmol), (4- chlorophenyl)boronic acid (834.08 mg, 5.33 mmol), Pd(dppf)Cl2(195.15 mg, 0.27 mmol) and K2CO3(152.70 mg, 1.10 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred for 3 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (30 mL) and the mixture was extracted with EtOAc 15 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed phase flash, eluted with CH3CN / H2O = 20 / 1 (v / v) to give ethyl 4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (112-1) (550.00 mg, 43.90%) as an off-white solid. MS (ESI, m / z): calcd. for C21H13ClF5N3O2: 469.1; Found: 470.1 [M + 1]+. Step 2. Synthesis of ethyl 9-bromo-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carboxylate (112-2). A solution of ethyl 4-(4-chlorophenyl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (112-1) (550.00 mg, 1.17 mmol) and NBS (416.74 mg, 2.34 mmol) in ACN (6 mL) was stirred for 2 h at 20 °C. The resulting mixture was diluted with water (10 mL). The reaction was quenched by the addition of NaHSO3(aq.) (10 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 5 / 1 (v / v) to give ethyl 9-bromo-4-(4- chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (112-2) (630.00 mg, 98.08%) as a light yellow solid. MS (ESI, m / z): calcd. for C21H12BrClF5N3O2: 547.0; Found: 548.0 [M + 1]+. Step 3. Synthesis of 9-bromo-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (112-3). A solution of ethyl 9-bromo-4-(4- chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate (112-2) (630.00 mg, 1.15 mmol) and NH2NH2•H2O (4.00 mL, 82.30 mmol) in EtOH (16 mL) was stirred for 3 h at 40 °C. The resulting mixture was concentrated under vacuum. Then the resulting mixture was diluted with brine (30 mL). The aqueous layer was extracted with CH2Cl2(20 mL x 2) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in 9-bromo-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-8-carbohydrazide (112-3) (600 mg, 97.74%) as an orange solid. MS (ESI, m / z): calcd. for C19H10BrClF5N5O: 533.0; Found: 533.9 [M + 1]+. Step 4. Synthesis of 2-(9-bromo-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (112-4). A solution of 9-bromo-4-(4-chlorophenyl)- 2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-8-carbohydrazide (112-3) (630.00 mg, 1.19 mmol) and TsOH (96.62 mg, 0.56 mmol) in CH(OCH3)3(6 mL) was stirred for 4 h at 70 °C. The mixture was allowed to cool down to room temperature. The mixture was basified to pH = 8 with saturated NaHCO3 (aq.). The resulting mixture was diluted with water (20 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 3 / 1 (v / v) to give 2-(9-bromo-4-(4-chlorophenyl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (112-4) (550.00 mg, 85.70%) as a yellow solid. MS (ESI, m / z): calcd. for C20H8BrClF5N5O: 543.0; Found: 543.9 [M + 1]+. Step 5. Synthesis of 2-(4-(4-chlorophenyl)-2-(perfluoroethyl)-9-vinylimidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (112-5). A solution of 2-(9-bromo-4-(4- chlorophenyl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (112-4) (550.00 mg, 1.01 mmol), tributyl(vinyl)stannane (640.43 mg, 2.02 mmol) and PdCl2(PPh3)2(99.23 mg, 0.14 mmol,) in dioxane (6 mL) was stirred for 2 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (20 mL) and the mixture was extracted with EtOAc (20 mL x 3) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (2:1) to give 2-(4-(4-chlorophenyl)-2-(perfluoroethyl)-9-vinylimidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (112-5) (430.00 mg, 86.58%) as a yellow solid. MS (ESI, m / z): calcd. for C22H11ClF5N5O: 491.1; Found: 492.1 [M + 1]+. Step 6. Synthesis of 4-(4-chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-9-carbaldehyde (112-6). A solution of 2- (4-(4-chlorophenyl)-2-(perfluoroethyl)-9-vinylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (112-5) (210.00 mg, 0.43 mmol), K2OsO4 (7.87 mg, 0.02 mmol) and NaIO4 (273.99 mg, 1.28 mmol) in acetone (8 mL) and H2O (2 mL) was stirred for 1 h at 0 °C. Then gradually returned to room temperature and stirred for 4 h. The resulting mixture was diluted with water (20 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed flash, eluted with CH3CN / H2O = 20 / 1 (v / v) to give 4-(4-chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridine-9-carbaldehyde (112-6) (100.00 mg, 47.43%) as a white solid. MS (ESI, m / z): calcd. for C21H9ClF5N5O2: 493.0; Found: 494.0 [M + 1]+. Step 7. Synthesis of (4-(4-chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)methanol (Example 112). To a solution of 4-(4-chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridine-9-carbaldehyde (112-6) (100.00 mg, 0.20 mmol) in THF (2 mL) was added NaBH4 (11.49 mg, 0.30 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. The reaction was quenched by the addition of Sat. NH4Cl (aq.) (5 mL) at room temperature. The resulting mixture was diluted with water (10 mL) and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% NH3·H2O) and ACN (25% ACN up to 95% in 7 min); Detector, UV254 nm, to give (4-(4- chlorophenyl)-8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-9- yl)methanol (Example 112) (24.00 mg, 23.90%) as an off-white solid. MS (ESI, m / z): calcd. for C21H11ClF5N5O2: 495.1; Found: 496.1 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.45 (s, 1H), 8.16 (s, 1H), 7.88 (d, J = 9.9 Hz, 1H), 7.76 - 7.68 (m, 5H), 5.67 (d, J = 6.3 Hz, 2H), 4.82 (t, J = 6.3 Hz, 1H) ppm. Table 4 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 4: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR = ), ), 4.81 (t, J = 6.3 Hz, 1H), 2.47 (s, 3H) ppm 5 = ), ), ) δ = ), z, s, 1H NMR (300 MHz, DMSO-d6): δ = ), d, t, = ), 1 = , 1H NMR (300 MHz, Acetonitrile-d3): , = ), ), , = ), Example 125. 2-(4-(4-Chlorophenyl)-9-ethyl-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin- 8-yl)-1,3,4-oxadiazole

[0006] Step 1. Synthesis of 2-(9-(2-(9-borabicyclo[3.3.1]nonan-9-yl)ethyl)-4-(4-chlorophenyl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (125-1). A solution of 2-(4-(4-chlorophenyl)-2-(perfluoroethyl)-9-vinylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (112-5) (150.00 mg, 0.31 mmol) and 9-BBN (1.50 mL, 0.62 mmol) in THF (2 mL) was stirred for 16 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was diluted with H2O (20 mL) and the mixture was extracted with EA (40 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:3 (v / v) to give 2-(9-(2-(9- borabicyclo[3.3.1]nonan-9-yl)ethyl)-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (125-1) (20.00 mg, 10.67%) as a yellow oil. MS (ESI, m / z): calcd. for C30H26BClF5N5O: 613.2; Found: 614.2 [M + 1]+. Step 2. Synthesis of 2-(4-(4-chlorophenyl)-9-ethyl-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 125). A solution of 2-(9-(2-(9- borabicyclo[3.3.1]nonan-9-yl)ethyl)-4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (125-1) (20.00 mg, 0.03 mmol) and H2O2(2 mL), NaOH (1.96 mg, 0.09 mmol) in THF (2 mL) was stirred for 4 h at -20°C under nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (10 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (20% Phase B to 80% in 11 min); Detector, UV 254 nm, to give 2-(4-(4-chlorophenyl)-9-ethyl-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (Example 125) (4.20 mg, 29%) as a white solid. MS (ESI, m / z): calcd. for C22H13ClF5N5O:493.1; Found: 494.0 [M + 1]+.1H NMR (300 MHz, Acetonitrile-d3): δ 8.77 (s, 1H), 7.98 (s, 1H), 7.73 – 7.65 (m, 4H), 7.60 – 7.57 (m, 2H), 4.09 - 4.02 (m, 2H), 1.49 -1.44 (m, 3H) ppm. Example 126. 2-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)ethan-1-ol Step 1. Synthesis of (E)-2-(9-(2-ethoxyvinyl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (126-2). A mixture of 2-(9-bromo-2- (perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (126-1) (220.00 mg, 0.42 mmol), 2-[(E)-2-ethoxyethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (332.48 mg, 1.68 mmol), Pd(PPh3)2Cl2(29.46 mg, 0.04 mmol) and K2CO3(175.26 mg, 1.26 mmol) in dioxane (10 mL) and water (1.5 mL) was stirred for 12 h at 100 °C under nitrogen atmosphere. After completion of the reaction, the mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (50 mL) and the mixture was extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 1 / 1 (v / v) to give (E)-2-(9-(2-ethoxyvinyl)-2- (perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (126-2) (190.00 mg, 87.84%) as a yellow solid. MS (ESI, m / z): calcd. for C25H18F5N5O2: 515.1; Found: 516.2 [M+1]+. Step 2. Synthesis of 2-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)acetaldehyde (126-3). To a stirred solution of (E)-2-(9-(2- ethoxyvinyl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (126-2) (190.00 mg, 0.36 mmol) in DCM (10 mL) were added TFA (2 mL) dropwise at 0 °C. The resulting mixture was stirred for 1 h at room temperature. After completion of the reaction, the resulting mixture was diluted with water (20 mL). The mixture was neutralized to pH = 7 with saturated NaHCO3 (aq.). The resulting mixture was extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% NH3·H2O) and ACN (20% ACN up to 95% in 5 min) to give 2-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin- 9-yl)acetaldehyde (126-3) (135.00 mg, 75.14%) as an off-white solid. MS (ESI, m / z): calcd. for C23H14F5N5O2: 487.1; Found: 488.1 [M+1]+.1H NMR (300 MHz, Acetonitrile-d3): δ 9.96 (s, 1H), 8.74 (s, 1H), 7.92 (s, 1H), 7.79 – 7.70 (m, 2H), 7.50 – 7.43 (m, 4H), 5.24 (s, 2H), 2.47 (s, 3H) ppm. Step 3. Synthesis of 2-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)ethan-1-ol (Example 126). To a stirred solution of 2-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)acetaldehyde (126-3) (135.00 mg, 0.27 mmol) in THF (7 mL) were added NaBH4(15.72 mg, 0.41 mmol) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature. After completion of the reaction, the resulting mixture was diluted with water (20 mL) and the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% NH3·H2O) and ACN (20% ACN up to 95% in 5 min) to give 2-(8-(1,3,4-oxadiazol- 2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)ethan-1-ol (Example 126) (38.00 mg, 28.03%) as a light yellow solid. MS (ESI, m / z): calcd. for C23H16F5N5O2: 489.1; Found: 490.1 [M+1]+.1H NMR (300 MHz, DMSO-d6): δ 9.40 (s, 1H), 8.05 (s, 1H), 7.82 (d, J = 9.6 Hz, 1H), 7.68 (d, J = 9.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 4.55 (t, J = 5.4 Hz, 1H), 4.16 (t, J = 6.6 Hz, 2H), 3.87 (t, J = 6.0 Hz, 2H), 2.46 (s, 3H) ppm. Table 5 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 5: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR , ), J Example 129. (8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methanamine

[0007] Synthesis of (8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methanamine (Example 129). A solution of 8-(1,3,4-oxadiazol-2-yl)- 2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridine-9-carbaldehyde (129-1) (100 mg, 0.21 mmol), NH3•H2O (74.04 mg, 2.11 mmol), AcOH (38.06 mg, 0.63 mmol) and NaBH(OAc)3(134.32 mg, 0.63 mmol) in THF (2 mL) was stirred for 5 h at room temperature. The reaction was quenched by the addition of water (20 mL) at room temperature and the resulting mixture was extracted with EtOAc (20mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% NH3·H2O) and ACN (25% ACN up to 90% in 8 min); Detector, UV254 nm, to give (8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p- tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)methanamine (Example 129) (10 mg, 9.98%) as a white solid. MS (ESI, m / z): calcd. for C22H15F5N6O: 474.1; Found: 475.3 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.44 (s, 1H), 8.09 (s, 1H), 7.85 (d, J = 9.9 Hz, 1H), 7.73 (d, J = 9.6 Hz, 1H), 7.56 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 4.82 (s, 2H), 2.46 (s, 3H), 2.40 - 2.01 (m, 2H) ppm. Example 130. 2-(2-(Perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-8-yl)- 1,3,4-oxadiazole Cl Step 1 Step 2 Step 3OH Step 1. Synthesis of 2,7-dichloro-4-(p-tolyl)pyrido[2,3-d]pyrimidine (130-2). A solution of 2,4,7-trichloropyrido[2,3-d]pyrimidine (130-1) (3.30 g, 14.08 mmol) and 4,4,5,5-tetramethyl-2- (p-tolyl)-1,3,2-dioxaborolane (6.14 g, 28.15 mmol), Pd(PPh3)4(0.81 g, 0.70 mmol), Na2CO3(4.52 g, 42.23 mmol) in dioxane (33 mL) was stirred for 4 h at 100°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (40 mL) and the mixture was extracted with EA (40 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:4 (v / v)) to give 2,7-dichloro-4-(p-tolyl)pyrido[2,3-d]pyrimidine (130-2) (820.00 mg, 20.08%) as a yellow solid. MS (ESI, m / z): calcd. for C14H9Cl2N3: 289.0; Found: 290.0 [M + 1]+. Step 2. Synthesis of 2-bromo-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-3). A solution of 2,7-dichloro-4-(p-tolyl)pyrido[2,3-d]pyrimidine (130-2) (820.00 mg, 2.87 mmol) in HBr in AcOH (33 %) (8 mL) was stirred for 2 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was diluted with H2O (30 mL). The mixture was basified to pH = 7~8 with NaHCO3 (aq). The resulting mixture was extracted with EA (30 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:2 (v / v)) to give 2-bromo-4-(p- tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-3) (530.00 mg, 59.32%) as a yellow solid. MS (ESI, m / z): calcd. for C14H10BrN3O: 315.0; Found: 316.1 [M + 1]+. Step 3. Synthesis of 2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-4). A solution of 2-bromo-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-3) (500.00 mg, 1.58 mmol) and TMSCF2CF3(1.22 g, 6.32 mmol), KF (918.79 mg, 15.81 mmol), CuI (1.51 g, 7.91 mmol) in DMSO (5 mL) was stirred for 2 h at 130°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (40 mL) and the mixture was extracted with EA (40 mL x 3). The combined organic layers were dried over anhydrous Na2SO4and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:2) to give 2-(perfluoroethyl)-4-(p- tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-4) (200.00 mg, 35.60%) as a yellow solid. MS (ESI, m / z): calcd. for C16H10F5N3O: 355.1; Found: 356.0 [M + 1]+. Step 4. Synthesis of 7-chloro-2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidine (130-5). A solution of 2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-ol (130-4) (200.00 mg, 0.56 mmol) in POCl3 (4 mL) was stirred for 3 h at 100°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (30 mL). The mixture was basified to pH = 7~8 with NaHCO3 (aq). The resulting mixture was extracted with EA (30 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:2 (v / v)) to give 7-chloro-2-(perfluoroethyl)-4-(p- tolyl)pyrido[2,3-d]pyrimidine (130-5) (110.00 mg, 52.29%) as a yellow solid. MS (ESI, m / z): calcd. for C16H9ClF5N3: 373.0; Found: 374.0 [M + 1]+. Step 5. Synthesis of 2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-amine (130-6). A solution of 7-chloro-2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidine (130-5) (110.00 mg, 0.29 mmol) and NH3(g) (501.30 mg, 29.40 mmol) in THF (5 mL) was stirred for 2 h at 60°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (30 mL) and the mixture was extracted with EA (30 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (3:1 (v / v)) to give 2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3-d]pyrimidin-7-amine (130-6) (90.00 mg, 86.30%) as a yellow solid. MS (ESI, m / z): calcd. for C16H11F5N4: 354.1; Found: 355.0 [M + 1]+. Step 6. Synthesis of ethyl 2-(perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidine-8-carboxylate. A solution of 2-(perfluoroethyl)-4-(p-tolyl)pyrido[2,3- d]pyrimidin-7-amine (130-6) (90.00 mg, 0.25 mmol) and ethyl 3-bromo-2-oxopropanoate (89.17 mg, 0.46 mmol) in DMF (2 mL) was stirred overnight at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (20 mL) and the aqueous layer was extracted with EA (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE (1:2 (v / v)) to give ethyl 2- (perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carboxylate (130-7) (60.00 mg, 52.44%) as a yellow solid. MS (ESI, m / z): calcd. for C21H15F5N4O2: 450.1; Found: 451.1 [M + 1]+. Step 7. Synthesis of 2-(perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine- 8-carbohydrazide (130-8). A solution of ethyl 2-(perfluoroethyl)-4-(p- tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carboxylate (130-7) (60.00 mg, 0.13 mmol) and NH2NH2•H2O (0.2 mL) in EtOH (2.0 mL) was stirred for 3 h at reflux under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. This resulted in 2-(perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidine-8-carbohydrazide (130-8) (140.00 mg, 68.29%) as a yellow solid. MS (ESI, m / z): calcd. for C19H13F5N6O: 436.1; Found: 437.0 [M + 1]+. Step 8. Synthesis of 2-(2-(perfluoroethyl)-4-(p-tolyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidin-8-yl)-1,3,4-oxadiazole (Example 130). A solution of 2-(perfluoroethyl)-4-(p- tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carbohydrazide (130-8) (30.00 mg, 0.06 mmol) and TsOH (5.92 mg, 0.03 mmol) in CH(OMe)3(2 mL) was stirred for 4 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (30% Phase B to 70% in 9 min); Detector, UV 254 nm, to give 2-(2-(perfluoroethyl)-4-(p- tolyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-8-yl)-1,3,4-oxadiazole (Example 130) (8.50 mg, 27.70%) as a yellow solid. MS (ESI, m / z): calcd. for C20H11F5N6O: 446.1; Found: 447.1[M + 1]+. 1H NMR (300 MHz, DMSO-d6): δ 9.46 (s, 1H), 9.17 (s, 1H), 7.99 (s, 2H), 7.78 - 7.77 (d, J = 8.1 Hz, 2H), 7.54 - 7.51 (d, J = 8.1 Hz, 2H), 2.48 (s, 3H) ppm. Table 6 shows structure and analytical data for representative Example of the present invention. The compound can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 6: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR 1H NMR (300 MHz, DMSO-d6): δ 9.47 (s, 1H), 9.20 (s, 1H), 8.04 – 7.95 (m, 2H), 7.91 – Example 132. (4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidin-4-yl)phenyl)methanol Step 1. Synthesis of ethyl 4-(4-(hydroxymethyl)phenyl)-2- (perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carboxylate (132-2). A solution of ethyl 4-(4-chlorophenyl)-2-(perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8- carboxylate (132-1) (220 mg, 0.47 mmol) and potassium (acetoxymethyl)trifluoroborate (126.15 mg, 0.7 mmol), Na2CO3 (75.00 mg, 0.7 mmol), Pd(dba)2(13.44 mg, 0.023 mmol), Ruphos (21.81 mg, 0.047 mmol) in H2O (0.2 mL) and dioxane (2 mL) was stirred for 24 h at reflux under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (70 mL) and extracted with EA (70 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (2:1 to 0:1 (v / v)) to give ethyl 4-(4-(hydroxymethyl)phenyl)-2- (perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carboxylate (132-2) (110 mg, 50.47%) as a yellow solid. MS (ESI, m / z): calcd. for C21H15F5N4O3: 466.1; Found: 467.1 [M + 1]+. Step 2. Synthesis of 4-(4-(hydroxymethyl)phenyl)-2- (perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carbohydrazide (132-3). A solution of ethyl 4-(4-(hydroxymethyl)phenyl)-2-(perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidine-8-carboxylate (132-2) (110 mg, 0.24 mmol) and NH2NH2•H2O (0.2 mL) in EtOH (2 mL) was stirred for 3 h at 70°C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in 4-(4-(hydroxymethyl)phenyl)-2- (perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine-8-carbohydrazide (132-3) (90 mg, 84.35%) as a yellow solid. MS (ESI, m / z): calcd. for C19H13F5N6O2: 452.1; Found: 453.2 [M + 1]+. Step 3. Synthesis of (4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-4-yl)phenyl)methanol (Example 132). A solution of 4-(4-(hydroxymethyl)phenyl)-2-(perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3- d]pyrimidine-8-carbohydrazide (132-3) (90 mg, 0.2 mmol) and TsOH (17.13 mg, 0.1 mmol) in CH(OMe)3(1 mL) was stirred for 4 h at 70°C under nitrogen atmosphere. The reaction was monitored by LCMS. After completion, the reaction mixture was allowed to cool down to room temperature. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (10 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep- HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (30% Phase B to 80% in 9 min); Detector, UV 254 nm, to give (4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-4- yl)phenyl)methanol (Example 132) (11 mg, 11.96%) as a white solid. MS (ESI, m / z): calcd. for C20H11F5N6O2: 462.1; Found: 463.3[M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.45 (s, 1H), 9.16 (s, 1H), 7.98 (s, 2H), 7.85 - 7.82 (m, 2H), 7.65 - 7.62 (m, 2H), 5.43 (t, J = 5.7 Hz, 1H), 4.66 (d, J = 5.7 Hz, 2H) ppm. Example 133. 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)phenyl acetate Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin- 4-yl)phenyl acetate (Example 133). A solution of 4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenol (Example 13) (120 mg, 0.27 mmol) and acetyl chloride (63.18 mg, 0.80 mmol) in pyridine (5 mL) was stirred for 1 h at 0 °C. The resulting mixture was diluted with water (20 mL). The resulting mixture was extracted with EtOAc (10 mL x 3), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: (Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (25% ACN up to 95% in 7 min); Detector, UV254 nm), to give 4-(8-(1,3,4-oxadiazol- 2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl acetate (Example 133) (40 mg, 30.47%) as an off-white solid. MS (ESI, m / z): calcd. for C22H12F5N5O3: 489.1; Found: 490.2 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.07 (s, 1H), 8.18 (s, 1H), 7.92 (d, J = 9.9 Hz, 1H), 7.80 - 7.73 (m, 3H), 7.44 (d, J = 8.4 Hz, 2H), 2.36 (s, 3H) ppm.

[0008] Example 134. 4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl isobutyrate Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin- 4-yl)benzyl isobutyrate (Example 134). A solution of (4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 51) (100.00 mg, 0.22 mmol) and isobutyric anhydride (68.58 mg, 0.43 mmol), 1-methylimidazole (35.59 mg, 0.43 mmol) in dioxane (2 mL) was stirred overnight at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (10 mL x 3). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (20% Phase B to 70% in 9 min); Detector, UV 254 nm, to give 4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl isobutyrate (Example 134) (20.00 mg, 17.36%) as a white solid. MS (ESI, m / z): calcd. for C25H18F5N5O3: 531.1; Found: 532.1[M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.07 (s, 1H), 8.15 (s, 1H), 7.91 (d, J = 9.9 Hz, 1H), 7.76 (d, J = 9.9 Hz, 1H), 7.72 – 7.69 (m, 2H), 7.65 –7.63 (m, 2H), 5.25 (s, 2H), 2.67 (p, J = 7.2 Hz,1H), 1.16 (d, J = 6.9 Hz, 6H) ppm. Example 135. 8-((8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methoxy)-8-oxooctanoic acid Synthesis of 8-((8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methoxy)-8-oxooctanoic acid (Example 135). To a stirred solution of octanedioic acid (27.12 mg, 0.16 mmol) and EDCI•HCl (29.84 mg, 0.16 mmol) in DMF (3 mL) were added (8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methanol (Example 113) (37.00 mg, 0.08 mmol) and DMAP (19.02 mg, 0.16 mmol). The resulting mixture was stirred overnight at 70 °C. After completion of the reaction, the mixture was allowed to cool down to room temperature. The reaction solution was directly purified by Pre-HPLC Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (20% ACN up to 95% in 5 min) to give 8-((8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)methoxy)-8- oxooctanoic acid (Example 135) (9.00 mg, 18.31%) as a white solid. MS (ESI, m / z): calcd. for C30H26F5N5O5: 631.2; Found: 632.2 [M+1]+.1H NMR (300 MHz, DMSO-d6): δ 9.47 (s, 1H), 8.09 (s, 1H), 7.91 (d, J = 9.9 Hz, 1H), 7.81 (d, J = 9.9 Hz, 1H), 7.57 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 6.21 (s, 2H), 2.46 (s, 3H), 2.24 (t, J = 7.5 Hz, 2H), 2.11 (t, J = 7.5 Hz, 2H), 1.49 – 1.38 (m, 4H), 1.23– 1.20 (m, 4H) ppm. Example 136. (8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methyl 2-hydroxyacetate Step 1. Synthesis of 2-(9-(chloromethyl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole (136-1). To a solution of (8-(1,3,4-oxadiazol-2-yl)- 2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)methanol (Example 113) (450 mg, 0.95 mmol) and TEA (143.69 mg, 1.42 mmol) in DCM (5 mL) was added MsCl (130.11 mg, 1.14 mmol) at 0°C and the reaction was stirred for 3 h at room temperature. The resulting mixture was diluted with water (20 mL) and the mixture was extracted with CH2Cl2(20 mL x 3). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF = 1 / 1 (v / v) to give 2-(9-(chloromethyl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)- 1,3,4-oxadiazole (136-1) (330 mg, 70.59%) as a yellow solid. MS (ESI, m / z): calcd. for C22H13ClF5N5O: 493.1; Found: 494.3 [M + 1]+. Step 2. Synthesis of (8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2- a][1,8]naphthyridin-9-yl)methyl 2-hydroxyacetate (Example 136). A solution of 2-(9- (chloromethyl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4- oxadiazole (136-1) (70 mg, 0.14 mmol) and sodium hydroxyacetate (27.79 mg, 0.28 mmol) in DMF (1 mL) was stirred for 2 h at 80 °C. The mixture was allowed to cool down to room temperature. The crude product was purified by prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, Water (0.5% FA) and ACN (25% ACN up to 90% in 8 min); Detector, UV254 nm, to give (8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)-4-(p-tolyl)imidazo[1,2-a][1,8]naphthyridin-9-yl)methyl 2- hydroxyacetate (Example 136) (29 mg, 38.35%) as a white solid. MS (ESI, m / z): calcd. for C24H16F5N5O4: 533.1; Found: 534.2 [M + 1]+.1H NMR (300 MHz, DMSO-d6): δ 9.48 (s, 1H), 8.10 (s, 1H), 7.92 (d, J = 9.9 Hz, 1H), 7.82 (d, J = 9.9 Hz, 1H), 7.58 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 6.27 (s, 2H), 5.37 (t, J = 6.6 Hz, 1H), 3.95 (d, J = 6.6 Hz, 2H), 2.47 (s, 3H) ppm. Example 137. 4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl 2-hydroxy-2-methylpropanoate Step 1. Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl methanesulfonate (137-1). To a stirred solution of (4-(8- (1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 51) (170 mg, 0.37 mmol) and TEA (111.86 mg, 1.10 mmol) in DCM (3 mL) was added methanesulfonyl chloride (84.41 mg, 0.74 mmol) at 0 °C. The resulting mixture was stirred for 3 h at room temperature. The reaction was quenched by the addition of water (5 mL) at 0 °C. The resulting mixture was extracted with CH2Cl2(5 mL x 3). The combined organic layers were washed with water (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give 4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl methanesulfonate (137-1) (180 mg, 90.56%) as a yellow solid. MS (ESI, m / z): calcd. for C22H14F5N5O4S: 539.1; Found: 540.4 [M+1]+. Step 2. Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl 2-hydroxy-2-methylpropanoate (Example 137). To a stirred solution of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl methanesulfonate (137-1) (80 mg, 0.15 mmol) and 2-hydroxy-2-methylpropanoic acid (30.88 mg, 0.30 mmol) in DMF (2 mL) was added K2CO3(61.49 mg, 0.44 mmol). The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was filtered, the filter cake was washed with DMF (2 mL).The crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Prep OBD C18 Column, 19*250 mm, 5 μm; Mobile Phase A: Water(0.05%NH3.H2O), Mobile Phase B: ACN; Flow rate: 25mL / min mL / min; Gradient: 40% B to70% B in 10 min; Wave Length: 254nm / 220nm nm; RT1(min): 6.67, to give 4-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl 2-hydroxy-2- methylpropanoate (Example 137) (15 mg, 18.48%) as a white solid. MS (ESI, m / z): calcd. for C25H18F5N5O4: 547.1; Found: 548.2[M+1]+.1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.07 (s, 1H), 8.16 (s, 1H), 7.91 (d, J = 9.6 Hz, 1H), 7.78 – 7.64 (m, 5H), 5.44 (s, 1H), 5.29 (s, 2H), 1.38 (s, 6H) ppm. Example 138. 4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl dimethyl phosphate Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin- 4-yl)benzyl dimethyl phosphate (Example 138). To a stirred solution of (4-(8-(1,3,4-oxadiazol- 2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 51) (80 mg, 0.17 mmol) and pyridine (1 mL) in DCM (3 mL) was added dimethyl phosphorochloridate (125.28 mg, 0.86 mmol) at 0°C. The resulting mixture was stirred overnight at room temperature. The reaction was quenched by the addition of water (5 mL) at 0°C. The resulting mixture was extracted with CH2Cl2(15 mL x 3). The combined organic layers were washed with water (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10mmol / L NH4HCO3+0.05NH3H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: isocratic 47%-77% 8min; Wave Length: 254nm / 220nm nm; RT1(min): 6.7, to give 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl dimethyl phosphate (Example 138) (18 mg, 18.23%) as a white solid. MS (ESI, m / z): calcd. for C23H17F5N5O5P: 569.1; Found: 570.1[M+1]+.1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.06 (s, 1H), 8.15 (s, 1H), 7.90 (d, J = 9.6 Hz, 1H), 7.77 – 7.68 (m, 5H), 5.21 (d, J = 8.0 Hz, 2H), 3.74 (s, 3H), 3.71 (s, 3H) ppm. Example 139. 4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl di-tert-butyl phosphate Example 140. 4-(8-(1,3,4-Oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl dihydrogen phosphate

[0009] Step 1. Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl di-tert-butyl phosphate (Example 139). To a stirred solution of {4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl methanesulfonate (137-1) (120 mg, 0.22 mmol) in DMF (3 mL) was added di-tert-butyl potassium phosphate (110.47 mg, 0.44 mmol). The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was diluted with water (5 mL) and the mixture was extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA = 1 / 1 (v / v) to give 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl di-tert-butyl phosphate (Example 139) (140 mg, 96.29%) as a white solid. MS (ESI, m / z): calcd. for C29H29F5N5O5P: 653.2; Found: 654.5 [M+1]+.1H NMR (300 MHz, CDCl3): δ 9.44 (s, 1H), 9.08 (s, 1H), 8.15 (s, 1H), 7.92 (d, J = 9.6 Hz, 1H), 7.78 – 7.66 (m, 5H), 5.10 (d, J = 7.2 Hz, 2H), 1.46 (s, 18H) ppm. Step 2. Synthesis of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl dihydrogen phosphate (Example 140). To a stirred solution of 4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl di- tert-butyl phosphate (Example 139) (140 mg, 0.21 mmol) in DCM (3 mL) was added TFA (1 mL). The resulting mixture was stirred for 3 h at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column: Sunfire Prep C18 OBD Column, 19*150mm, 5μm; Mobile Phase A: Water(0.1% TFA), Mobile Phase B: ACN; Flow rate: 30 mL / min mL / min; Gradient: 25% B to 45% B in 8 min; Wave Length: 254nm / 220nm nm; RT1(min): 6.95, to give 4-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl dihydrogen phosphate (Example 140) (8 mg, 6.90%) as a white solid. MS (ESI, m / z): calcd. for C21H13F5N5O5P: 541.1; Found: 542.2[M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 11.3 (brs, 1H) 9.42 (s, 1H), 9.03 (s, 1H), 8.12 (s, 1H), 7.86 (d, J = 10.0 Hz, 1H), 7.74 (d, J = 9.6 Hz, 1H), 7.66 (s, 4H), 5.04 (d, J = 7.2 Hz, 2H) ppm. Table 7 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 7: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR , ), 9 1H NMR (400 MHz, DMSO-d6): δ 9.42 = , z, J , z, J , 1H NMR (300 MHz, DMSO-d6): δ 9.47 z, J , z, 8 , 1H NMR (300 MHz, DMSO-d6): δ 9.46 - , z, J , z, J , ,

[0010] 1H NMR (300 MHz, DMSO-d6): δ 9.47 z, J , z, , z, , ), - 1H NMR (300 MHz, DMSO-d6): δ 9.43 ), ), , ), 1H NMR (300 MHz, DMSO-d6): δ 9.12 (s, 1H), 8.77 (s, 1H), 8.02 (s, 1H), 7.82 – – ), – – t, s, 1H NMR (300 MHz, DMSO-d6): δ 9.44 , ), , z, J , z, Example 169. Isopropyl ((R)-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L-alaninate Example 170. Isopropyl ((S)-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L-alaninate Step 1. Synthesis of isopropyl (((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L-alaninate (169-1). To a stirred solution of (4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)phenyl)methanol (Example 51) (140 mg, 0.30 mmol) and isopropyl ((S)- (perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate (206.34 mg, 0.46 mmol) in THF (3 mL) were added MgCl2(57.78 mg, 0.61 mmol) and DIEA (58.83 mg, 0.46 mmol). The resulting mixture was stirred overnight at 60 °C. The reaction was quenched by the addition of water (5 mL) and the mixture was extracted with EtOAc (3 x 5mL). The combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column: Xselect CSH-Prep C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water(0.1 FA), Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: isocratic 48%-63% 14min; Wave Length: 254nm / 220nm nm; RT1(min): 10.37, to give isopropyl (((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4- yl)benzyl)oxy)(phenoxy)phosphoryl)-L-alaninate (169-1) (30 mg, 13.53%) as a white solid. MS (ESI, m / z): calcd. for C33H28F5N6O6P: 730.2; Found: 731.2 [M + 1]+. Step 2. Synthesis of isopropyl ((R)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 169), isopropyl ((S)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 170). The isopropyl (2S)-2-[({4-[8-(1,3,4-oxadiazol-2-yl)-2-(1,1,2,2,2- pentafluoroethyl)imidazo[1,2-a]1,8-naphthyridin-4- yl]phenyl}methoxy(phenoxy)phosphoryl)amino]propanoate (169-1) (30 mg) was purified by Prep-chiral-HPLC with the following conditions: Column: XA-CHIRAL ART Cellulose-SZ, 3*25cm 5um; Mobile Phase A: Hexane: DCM=3: 1 (HPLC grade), Mobile Phase B: IPA: ACN=5: 1; Flow rate: 35 mL / min; Gradient: isocratic 80; Wave Length: 254 nm; RT1(min): 7.4; RT2(min): 9.5; Sample Solvent: IPA: DCM=1: 1 (HPLC grade); Injection Volume: 4 mL; Number Of Runs: 4 to give isopropyl ((R)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 169) (3.5 mg), and isopropyl ((S)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 170) (23 mg) as white solids. Isopropyl ((R)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 169). MS (ESI, m / z): calcd. For C33H28F5N6O6P: 730.2; Found: 731.2 [M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.08 (s, 1H), 8.14 (s, 1H), 7.91 (d, J = 10.0 Hz, 1H), 7.76 (d, J = 10.0 Hz, 1H), 7.72 - 7.67 (m, 4H), 7.41 – 7.37 (m, 2H), 7.24 – 7.18 (m, 3H), 6.20 - 6.11 (m, 1H), 5.25 (d, J = 7.6 Hz, 2H), 4.90 - 4.85 (m, 1H), 3.86 - 3.81 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H), 1.18 - 1.15 (m, 6H) ppm. Isopropyl ((S)-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)(phenoxy)phosphoryl)-L- alaninate (Example 170). MS (ESI, m / z): calcd. For C33H28F5N6O6P: 730.2; Found: 731.2 [M + 1]+.1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.07 (s, 1H), 8.12 (s, 1H), 7.91 (d, J = 10.0 Hz, 1H), 7.74 (d, J = 9.6 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.42 – 7.38 (m, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 7.6 Hz, 1H), 6.18 - 6.12 (m, 1H), 5.22 - 5.20 (m, 2H), 4.89 - 4.86 (m, 1H), 3.86 (d, J = 7.2 Hz, 1H), 1.26 (d, J = 6.8 Hz, 3H), 1.16 - 1.13 (m, 6H) ppm. Table 8 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. The stereochemistry of these pure enantiomers was arbitrarily assigned. Table 8: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR s, = – – – 0 8 H) s, = – – d, 8 s, = – – – ), 4.01– 3.89 (m, 3H), 1.49 – 1.41 (m, 1H), 1.30– 1.26 (m, 6H), 1.25 – 1.23 (m, 1H), . , , , , a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide Example 175. (2S,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide Step 1. Synthesis of (4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)pyrrolo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (Example 174-1). A solution of (4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)phenyl)methanol (Example 51) (100 mg, 0.22 mmol) in THF (2 mL) was treated with LDA (116.10 mg, 1.09 mmol) for 0.5 h at 0°C under nitrogen atmosphere followed by the addition of (4S)-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane 2-oxide (160.26 mg, 0.43 mmol) dropwise at 0°C. The resulting mixture was stirred for 1.5 h at 0°C under nitrogen atmosphere. The reaction was quenched with H2O (10 mL) and the aqueous layer was extracted with EA (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO2. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: XSelect C18 Column, 5um, 19 * 150 mm; mobile phase, water (0.1% NH3•H2O) and MeCN (30% Phase B to 70% in 9 min); Detector, UV 254 nm, to give (4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)pyrrolo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (174- 1) (25 mg, 16.50%) as a white solid. Step 2. Synthesis of (2R,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (Example 174) & (2S,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (Example 175). The sample of (4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)pyrrolo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2- dioxaphosphinane 2-oxide (174-1) was purified by Prep-SFC with the following conditions: XSelect Column: XA-CHIRAL ART Cellulose-SB, 3*25cm 5um; Mobile Phase A: CO2, Mobile Phase B: MEOH: DCM=2: 1(0.1% 2M NH3-MeOH); Flow rate: 80 mL / min; Gradient: isocratic 50% B; Column Temperature (℃): 35; Back Pressure(bar): 100; Wave Length: 254 nm; RT1(min): 5.35; RT2(min): 8.75; Sample Solvent: MeOH: DCM = 2: 1; Injection Volume: 8 mL. This resulted in (2R,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2- a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (Example 174) (22.0 mg) and (2S,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2- dioxaphosphinane 2-oxide (Example 175) (2.8 mg) as white solids. (2R,4S)-2-((4-(8-(1,3,4- oxadiazol-2-yl)-2-(perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3- chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide (Example 174). MS (ESI, m / z): calcd. for C30H20ClF5N5O5P: 691.1; Found: 692.1[M + 1]+.1H NMR (300 MHz, Acetonitrile-d3): δ 9.14 (s, 1H), 8.77 (s, 1H), 7.99 (s, 1H), 7.77 – 7.75 (m, 1H), 7.74 – 7.70 (m, 3H), 7.66 – 7.64 (m, 2H), 7.45 – 7.33 (m, 4H), 5.48 (d, J = 9.9 Hz, 1H), 5.29 (d, J = 9.0 Hz, 2H), 4.54 – 4.42 (m, 2H), 2.29 – 2.22 (m, 1H), 2.09 – 2.04 (m, 1H) ppm. (2S,4S)-2-((4-(8-(1,3,4-oxadiazol-2-yl)-2- (perfluoroethyl)imidazo[1,2-a][1,8]naphthyridin-4-yl)benzyl)oxy)-4-(3-chlorophenyl)-1,3,2- dioxaphosphinane 2-oxide (Example 175). MS (ESI, m / z): calcd. for C30H20ClF5N5O5P: 691.1; Found: 692.1[M + 1]+. 1H NMR (300 MHz, Acetonitrile-d3) δ 9.14 (s, 1H), 8.77 (s, 1H), 8.02 (s, 1H), 7.79 – 7.76 (m, 2H), 7.69 – 7.64 (m, 4H), 7.46 (s, 1H), 7.42 – 7.35 (m, 3H), 5.71 (d, J = 11.1 Hz, 1H), 5.32 (d, J = 9.0 Hz, 2H), 4.69 – 4.60 (m, 1H), 4.55– 4.45 (m, 1H),2.40 – 2.34 (m, 1H), 2.23 (s, 1H) ppm. Table 9 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. The stereochemistry of these pure enantiomers was arbitrarily assigned. Table 9: Analytical data of representative compounds Example Structure MS [M + 1]+ 1H NMR d, ) VI Biological Data IFNα pathway induction HEK293 cells expressing the firefly luciferase gene under the control of ISRE stably integrated into HEK293 cells were obtained from BPS Bioscience. ISRE reporter was used to measure IFNα pathway induction. Upon IFNα stimulation, pospho-STAT1 and phosphor-STAT2 form a complex with IRF9, named as ISGF3, which translocates to the nucleus and activates the transcription of interferon inducible genes (ISGs) through binding to ISRE in the promoter region of ISGs. The cells were culture in MEM medium (Corning) supplemented with 10% FBS, 1% non- essential amino acids, 1 mM sodium pyruvate, 1% Penicillin / Streptomycin plus 400 µg / ml of Geneticin. Sub-confluent culture is passaged and split twice a week, not exceeding 30 passages. Cells are detached using 0.05% Trypsin / 0.53mM EDTA solution (Corning). For testing the compound effect on IFNα pathway, HEK293 ISRE reporter cells were seeded in 96-well plate at density of 50,000 cells / well 24 hours before treatment in a black clear bottom plate (Corning). Next day, the cells were treated with compounds in a three-fold serial dilution. The final DMSO concentration in each well is normalized to 0.5%. After 24-hour incubation, the activity of ISRE induction was measured using One-Glo luciferase substrate (Promega) on a Tecan Infinite M1000 Pro plate reader. The fold of induction was calculated by the activity of compound treated cells relative to DMSO treated cells. Cell-based HCV replicon assay HCV 1b replicon (NanoLuc luciferase) cell line was generated in Huh7-Lunet cells. HCV replicon cells were cultured in DMEM medium (Cytiva) supplemented with 10% FBS, 1% Penicillin / Streptomycin plus 250 µg / ml of Geneticin. Sub-confluent culture of HCV replicon is passaged and split twice a week, not exceeding 40 passages. Cells are detached using 0.25% Trypsin / 2.21 mM EDTA solution (Corning). For testing the antiviral activity of compounds, HCV 1b replicon cells were seeded in DMEM medium supplemented with 5% FBS and 1% % Penicillin / Streptomycin at a density of 5,000 cells / well in a black clear bottom half-well 96-well plate (Corning), following by the addition of compounds in a three-fold serial dilution. The final DMSO concentration in each well is normalized to 1%. After 48-hour incubation, the luciferase activity was measured using Nano- Glo luciferase substrate (Promega) on a Tecan Infinite M1000 Pro plate reader. The antiviral activity of compound was calculated from the percentage of luciferase signals relative to DMSO treated cells. Table 10 provides assay data for exemplified compounds of the invention. The antiviral activity of the exemplified compounds at 20 uM is grouped in the following ranges: A indicates < 25%; B indicates 25% to 50%; C indicates > 50%. The ISRE induction of the exemplified compounds at 20 uM is grouped in the following ranges: A indicates greater than 2 folds; B indicates = 0.5-2 fold(s). Table 10. Assay data for exemplified compounds of the invention. Example Antiviral Activity ISRE Induction 23 A A 24 B B 53 B B 54 A A 83 A B 84 A A 113 A A 114 C B 143 A A 144 A A 173 A A 174 A B All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. EQUIVALENTS While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. Although this specification contains many specific implementation details, these should not be construed as limitations on the scope of any disclosure or on the scope of what may be claimed, but rather as descriptions of features that may be specific to particular implementations of particular disclosures. Certain features that are described in this specification in the context of separate implementations may also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation may also be implemented in multiple implementations separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination may in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or variation of a sub-combinations. Particular implementations of the subject matter have been described. Other implementations, alterations, and permutations of the described implementations are within the scope of the following claims as will be apparent to those skilled in the art. For example, the actions recited in the claims may be performed in a different order and still achieve desirable results. Accordingly, the above description of example implementations does not define or constrain this disclosure. Other changes, substitutions, and alterations are also possible without departing from the spirit and scope of this disclosure. A number of embodiments of the present disclosure have been described. Although this specification contains many specific implementation details, the specific implementation details should not be construed as limitations on the scope of any disclosures or of what may be claimed, but rather as descriptions of features specific to particular embodiments of the present disclosure. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the claimed disclosure.

Claims

CLAIMS:

1. A compound of Formula I a I , or a pharmaceuticallyX0is O or S; X1is N or CH; X2is O or S; Raand Rbare independently selected for each occurrence from the group consisting of hydrogen and C1-4alkyl; R0is haloC1-6alkyl or monoC3-7cycloalkyl; R1is selected from the group consisting of: ,R3is hydrogen, halo, OH cyano, formyl, C1-4alkyl, haloC1-4alkyl, C1-4alkenyl, haloC1-4alkenyl, formylC1-4alkyl, hydroxyC1-4alkyl, RaRbN-alkyl-, C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl-, phenylC(O)OC1-4alkyl- or R5R6P(O)OC1-4alkyl-; R4is independently selected for each occurrence from the group consisting of halo, OH, CN, NO2, NRaRb, RaRbNC(O)-, carboxyl, formyl, C1-4alkyl, haloC1-4alkyl, carboxyC1-4alkyl-, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxyC1-5alkyl-, C1-4alkoxy, haloC1-4alkoxy,C1-4alkylC(O)-, haloC1-4alkylC(O)-, C1-4alkylC(O)O-, haloC1-4alkylC(O)O-, C1-4alkylSO2-, haloC1-4alkylSO2-, C1-4alkoxyC1-5alkyl-, haloC1-4alkoxyC1-5alkyl-, C1-4alkylC(O)OC1-5alkyl-, haloC1-4alkylC(O)OC1-5alkyl-, C1-4alkoxyC(O)C1-5alkyl-, haloC1-4alkoxyC(O)C1-5alkyl-, phenylC(O)OC1-4alkyl-, C1-4alkoxyC(O)OC1-4alkyl-, C1-4alkoxyC1-5alkyl-O-, haloC1-4alkoxyC1-5alkyl-O-, C1-4alkoxyC1-5alkyl-NRa-, haloC1-4alkoxyC1-5alkyl-NRa-, C1-4alkoxyC(O)OC1-5alkyl-, haloC1-4alkoxyC(O)OC1-5alkyl-, hydroxyC1-4alkylC(O)OC1-4alkyl-, C1-4alkoxyC(O)-C1-4alkylene-C(O)OC1-4alkyl-, C1-4alkoxyC(O)-C1-4alkenylene-C(O)OC1-4alkyl-, carboxyC1-4alkylC(O)OC1-4alkyl-, carboxyC1-4alkenylC(O)OC1-4alkyl-, R7R8P(O)OC1-4alkyl-, CH3CH2O- (CH2CH2O)n-C1-4alkyl-, CH3CH2O-(CH2CH2O)n-CH2CH2C(O)OC1-4alkyl-, CH3CH2O- (CH2CH2O)n-C(O)OC1-4alkyl-, monoC3-7cycloalkyl, phenyl and pyridyl, wherein the monoC3-7cycloalkyl, phenyl and pyridyl is optionally substituted with 1-3 groups independently selected from the group consisting of halo, OH, C1-4alkyl and haloC1-4alkyl; R4ais hydrogen or C1-4alkyl; R5, R6, R7and R8are independently selected from the group consisting of: OH, C1-4alkoxy, phenoxy, C1-4alkylC(O)O-C1-4alkylene-O- and C1-6alkoxyC(O)-C1-4alkylene-NRa-; or R5and R6together form a -OCH2CH2CH2O- group optionally substituted with a phenyl or pyridyl, wherein the phenyl or pyridyl is optionally substituted with halo; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. x is 0 or 1; w is 0, 1 or 2; and v is 0, 1, 2 or 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R0is CF3, CF3CF2or CF3CF2CF2.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R0is CF3CF2.

4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: .

5. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R2is hydrogen.

6. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R3is hydrogen.

7. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R3is C1-4alkyl, haloC1-4alkyl, C1-4alkenyl, haloC1-4alkenyl, formylC1-4alkyl, hydroxyC1-4alkyl, RaRbN-alkyl-, C1-6alkylC(O)OC1-4alkyl-, hydroxyC1-6alkylC(O)OC1-4alkyl-, carboxyC1-6alkylC(O)OC1-4alkyl-, RaRbNC1-6alkylC(O)OC1-4alkyl-, phenylC(O)OC1-4alkyl- or R5R6P(O)OC1-4alkyl-.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R3is R3is hydroxyC1-4alkyl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R3is R3is HOCH2- or HOCH2CH2-.

10. A pharmaceutical composition comprising: a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

11. A method of treating a viral infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein the viral infection is an HBV infection.

13. The method of claim 11, wherein the viral infection is an HDV infection.

14. The method of claim 11, wherein the viral infection is an HSV infection.

15. A method of treating a viral infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 10.

16. The method of claim 15, wherein the viral infection is an HBV infection.

17. The method of claim 15, wherein the viral infection is an HDV infection.

18. The method of claim 15, wherein the viral infection is an HSV infection.

Images